

**Author Index for 1996**

Abbruzzese, M., 58:37
Achiron, A., 58:177
Ackenheil, M., 59:7
Adams, P.B., 57:169
Addis, I.B., 56:111
Adès, J., 59:255
Adinoff, B., 59:127
Agbayewa, O., 60:33
Agras, W.S., 58:13
Akerman, D., 56:11
Akers, L., 60:41
Albers, L.J., 57:275, 59:189, 60:177
Alpert, R., 60:167
Ancoli-Israel, S., 57:7
Anderson, B., 56:17
Anderson, J., 56:229, 56:237, 58:69
Apter, S., 57:109
Arbisi, P.A., 59:171
Armitage, R., 56:245
Arnow, B., 58:13
Aronson, A., 59:127
Asmundson, G.J.G., 59:183
Asnis, G.M., 60:191
Avanzini, P., 58:153

Bagby, R.M., 58:139
Balon, R., 56:289, 60:77
Bar-Ziv, J., 58:259
Barak, Y., 58:177
Bardgett, M.E., 58:117
Barker, B.A., 57:83
Barry, R.J., 56:229, 56:237, 58:69
Bartlett, E.J., 60:91
Barzega, G., 57:49
Bastürk, M., 59:165
Batra, A., 59:251
Baumgartner, A., 56:81
Beam-Goulet, J., 56:45
Bean, G., 59:109
Beckmann, P., 56:257
Beckmann, H., 59:17
Beiser, M., 56:145, 59:109
Bell, M., 56:45
Bellack, A.S., 56:121, 57:141
Bellino, S., 57:49

Bellodi, L., 57:267, 58:265
Benson, K.L., 60:125
Berchou, R., 56:289, 60:77
Bergman, A., 57:131
Berrios, G.E., 56:183
Bertollo, D.N., 60:113
Beumont, P.J.V., 56:229, 56:237
Bielski, R.J., 56:221
Bierer, L.M., 58:181
Bierhals, A.J., 59:65
Bird, H., 57:169
Blanchard, J.J., 57:141
Bleich, A., 58:259
Blouin, J.H., 60:1
Blouin, A.G., 60:1
Bodeau-Péan, S., 59:1
Bogetto, F., 57:49
Bonato, R., 56:245
Bondoux, D., 58:191
Bondy, B., 59:7
Booker, J.M., 57:251
Bouhuys, N., 57:223
Bourdell, M.-C., 57:41
Boutros, N.N., 57:57, 57:83
Bouvard, M.P., 58:191, 59:255, 60:101
Boyer, P., 60:57
Brambilla, F., 58:153, 59:43, 59:51
Bräunig, P., 57:21
Breier, A., 56:33
Brekke, J.S., 57:241
Bremner, J.D., 59:97
Breslau, N., 58:1
Brodie, J.D., 60:91
Bröker, M., 58:77
Brown, A.S., 57:231
Brown, R.J., 56:53
Bruce, B., 58:13
Brunetta, M., 59:43, 59:51
Brunner, J., 58:165
Bryant, N.L., 56:33
Buchanan, R.W., 56:33, 59:221
Buitelaar, J.K., 58:203
Burgess, A., 56:71
Burns, E.M., 57:57
Buss, T.J.R., 59:197
Byrne, M., 59:119

Caccavari, R., 58:153
Calabrese, J., 58:217
Caldirola, D., 57:267
Caligiuri, M.P., 57:279
Calloway, S.P., 56:183
Campeas, R.B., 58:127
Campion, D., 59:1, 59:25
Cancro, R., 60:91
Cannon, M., 59:119
Capelli, S., 59:97
Carbone, K.M., 56:33
Carey, G., 56:213
Caro, F., 58:45
Carpenter, W.T., Jr., 56:33
Carter, C.S., 56:59
Carter, J., 60:1
Casella, N.G., 58:53
Cassidy, B., 59:119
Castro, J.O., 60:23
Censits, D.M., 60:135
Cestaro, V., 60:167
Chaderjian, M., 56:59
Chang, W.-H., 57:101
Chang, L.-S., 57:65
Charney, D.S., 59:97
Chartier, M.J., 59:183
Chen, C.-C., 57:197
Chen, E.Y.H., 56:183
Chen, Y.-W., 59:57
Chhay, H., 60:177
Chien, C.-P., 57:101
Chung, M.-C., 57:101
Cinotti, L., 60:101
Clark, W.C., 56:173
Claus, D., 56:279
Cloitre, M., 59:245
Cohen, L.J., 58:161
Convit, A., 59:161
Cook, E.H., Jr., 57:13
Cooke, R.G., 58:139
Cooper, T.B., 59:161
Coplan, J.D., 58:127
Cordas, T.A., 56:11
Cornblatt, B., 57:131
Cornwell, A., 58:247
Corrigan, P.W., 56:111

Cottraux, J., 60:101
 Cowen, M.A., 60:113
 Crocq, M.-A., 60:23
 Csernansky, J.G., 58:117
 Cuesta, M.J., 58:45, 58:227

d'Amato, T., 59:1, 60:205
 Daléry, J., 60:205
 Daveloose, D., 59:255
 Davidson, M., 57:109, 59:127, 60:87
 Davies, S.O., 58:127
 Davis, S., 56:163
 Davis, K.L., 57:109, 58:181
 Davis, L.L., 60:41
 Daviss, S.R., 59:81
 DeCaria, C., 58:161
 DeCarli, C., 57:119
 Deiber, M.-P., 60:101
 de Jong, J., 58:83
 Deka, R., 59:35
 Delaney, R., 59:97
 de Leon, J., 58:45
 Delsignore, R., 58:153
 DeMet, E.M., 57:197
 Dening, T.R., 56:183
 Desnyder, R., 58:217
 deVegvar, M.L., 59:127
 Dewart, D., 58:247
 Dewey, S.L., 60:91
 Dhalla, K.S., 59:183
 Dietrich, M., 59:251
 Dillon, D.J., 58:127
 Dilsaver, S.C., 59:57
 Dogan, P., 59:165
 Dollfus, S., 59:1
 Doman, J., 59:65
 Draisici, A., 59:43
 Dugas, M., 58:191, 59:255
 Dunayevich, E., 57:209
 DuPre, R., 60:49
 Duval, F., 60:23
 Dworkin, R.H., 56:173

Egan, M.F., 56:53
 Eisdorfer, C., 59:145
 El-Mallakh, R.S., 59:197
 Ellison, T., 57:13
 Ercegovac, D.V., 58:247
 Erzegovesi, S., 58:265
 Esel, E., 59:165

Faraone, S.V., 56:135
 Fasiczka, A., 59:65
 Fava, M., 56:205, 56:295
 Fell, J., 56:257
 Ferri, S., 58:37
 Fertonani, G., 58:153

Fishman, B., 59:245
 Fitch, T., 56:245
 Fleming, K., 56:155
 Flores, C.V., 56:101
 Frank, E., 56:17, 59:65
 Franzek, E., 59:17
 Freedman, R., 56:271
 Friedland, N., 58:259
 Friedman, J.H., 57:231
 Froment, J.-C., 60:101
 Fyer, A.J., 58:127

Gabriele, A., 57:267
 Galinowski, A., 57:41
 Gallacher, F., 60:135
 Galy, G., 60:JC
 Garvey, M.J., 57:1, 60:185
 Gattaz, W.F., 58:165
 Geerts, E., 57:223
 Gérard, D., 60:101
 Gerra, G., 58:153
 Gevirtz, R., 57:7
 Giannelli, A., 56:295
 Gillin, J.C., 58:23, 58:99
 Glahn, D.C., 60:135
 Glicksohn, J., 58:259
 Gold, J.M., 56:155
 Goldberg, T.E., 56:155
 Goldfield, G., 60:1
 Goldstein, C., 60:1
 Goldstein, M.J., 57:155
 Golshan, S., 58:99
 Gonsalvez, C.J., 56:237, 58:69
 Gönül, A.S., 59:165
 Goossens, F., 58:217
 Gordon, B., 57:75
 Gordon, E., 56:229, 56:237, 58:69
 Gorman, J.M., 57:231, 58:127
 Gottesman, I.I., 56:213
 Gräf, K.-J., 56:81
 Griffith, J.M., 56:271
 Gross, G., 57:21
 Gruzelier, J., 56:71, 56:163
 Guaraldi, G.P., 56:295
 Guillaud-Bataille, J.-M., 60:205
 Guo, S.L., 57:109
 Gur, R.C., 60:135
 Gur, R.E., 60:135
 Gurklis, J.A., 60:11
 Gurrera, R.J., 56:25
 Gynther, L.M., 56:213

Halaris, A., 57:21
 Hallmayer, J., 59:7
 Harvey, P.D., 59:127, 60:49, 60:87
 Hauger, R.L., 58:23, 59:183
 Hedley, L.M., 56:1

Heinz, A., 56:81
 Helmeste, D., 57:275, 59:189, 60:177
 Hembree, W.C., 57:231
 Herzog, D.B., 56:205
 Heuser, I., 59:157
 Hilwig, M., 56:299
 Hodges, J.R., 56:183
 Hoff, A.L., 60:167
 Hoffart, A., 56:1
 Hoffmann, R., 56:245
 Hofman, A., 56:299
 Holcomb, H.H., 57:75, 58:53
 Hollander, E., 58:161
 Holsboer, F., 59:157
 Honig, A., 56:299
 Horgan, R., 59:119
 Horvath, T.B., 57:109
 Horwitz, B., 57:119
 Houck, P.R., 56:17
 Hoven, C.W., 57:169
 Huang, H.-F., 57:101
 Huang, Y.-H., 57:65
 Huber, G., 57:21
 Huggins, T.S., 57:259
 Husted, J.A., 56:145
 Huttunen, M.O., 58:145
 Hwang, M., 58:161
 Hyde, T.M., 56:53
 Hymas, N.F.S., 56:183

Iacono, W.G., 56:145, 59:109
 Irving, G., 56:71
 Islam, N., 58:161
 Iversen, H., 60:1
 Iwata, N., 58:237

Jackson, J.L., 58:117
 Jackson, P., 58:247
 Jacobsberg, L., 59:245
 Jacobson, R., 58:181
 Jann, M.W., 57:101
 Jansen, J., 57:223
 Jay, M., 59:1, 59:25, 60:205
 Jenck, F., 57:181
 Jerushalmi, Z., 57:193
 Joffe, R.T., 58:139

Kallio, E., 58:145
 Kaplan, Z., 60:199
 Kärkkäinen, J., 58:145
 Kaschka, W.P., 56:279
 Kasper, S., 56:11
 Katz, M., 57:275
 Kaufmann, C.A., 57:231
 Kawakami, N., 58:237
 Keck, P.E., Jr., 57:209
 Keefe, R.S.E., 59:127, 60:49

Kellner, M., 59:157
 Kelsoe, J.R., 58:99
 Kenny, W.M., 58:99
 Keshavan, M.S., 57:91, 59:203, 60:117
 Kikinzon, L., 57:193
 Kim, C., 59:221
 Klein, D.F., 58:127
 Klein, R., 59:251
 Kleinman, J.E., 56:53
 Klemfuss, H., 57:215
 Kling, M.A., 57:259
 Koran, L.M., 58:13
 Köse, K., 59:165
 Koziol, J.A., 59:239
 Kraemer, H.C., 58:13
 Krakowski, H., 59:161
 Kramer, G.L., 59:127, 60:41
 Kremen, W.S., 56:135
 Krener, P., 56:59
 Kripke, D.F., 57:215
 Krishnan, R.R., 60:117
 Kumar, M., 59:145
 Kumar, A.M., 59:145
 Kunz, M., 59:161
 Kupfer, D.J., 56:17, 57:91
 Kürten, I., 56:81

Labbé, C., 60:101
 Lahti, A., 59:221
 Lam, R.W., 60:33
 Lampl, Y., 58:177
 Larkin, C., 59:119
 Laukes, C., 57:1
 Launay, J.-M., 58:191
 Laurent, C., 59:1
 Lauriello, J., 58:99, 60:125
 Lavenne, F., 60:101
 Lawlor, B.A., 58:181
 Le Bars, D., 60:101
 Lebell, M.B., 57:155
 Leboyer, M., 58:191
 Lees-Roitman, S., 59:127, 60:49
 Lefton, R.S., 56:101
 Lejoyeux, M., 59:255
 Lensing, P., 58:191
 Leonard, H.L., 60:67
 Leventhal, B.L., 57:13
 Levine, A.S., 59:171
 Levine, J., 60:199
 Levitt, A.J., 58:139
 Levy, A.V., 60:113
 Lewis, D.A., 59:81
 Li, R., 59:197
 Lichtermann, D., 59:7
 Liebowitz, M.R., 58:127
 Lim, K.O., 60:125
 Lipsitz, J.D., 56:173

Lish, J.D., 57:169
 Loas, G., 60:57
 Lohr, J.B., 57:279
 Lombardi, J., 60:87
 Lôô, H., 57:41
 Losonczy, M., 57:109
 Lovell, B.B., 57:7
 Lupien, S., 58:23
 Luque, R., 56:183
 Lyons, M.J., 56:135
 Lysaker, P., 56:45

Macher, J.-P., 60:23
 Maciejewski, P.K., 59:65
 Maes, M., 58:89, 58:217
 Maestri, D., 58:153
 Maier, W., 59:7
 Maina, G., 57:49
 Mallet, J., 59:1
 Manfredi, B., 59:43, 59:51
 Marder, S.R., 57:155
 Marin, D.B., 58:181
 Marler, M., 57:21
 Martin, J.R., 57:181
 Martinez, M., 59:1, 59:25
 Martinez, J., 58:127
 Mauguière, F., 60:101
 Mayo, A.L., 56:17
 Mayor, J., 56:221
 McCarthy, G., 59:97
 McElroy, S.L., 57:209
 McGarvey, K., 60:33
 McGinn, L.K., 60:191
 McIntosh, A.R., 57:119
 McKenna, P.J., 56:183
 Meares, R., 56:229, 56:237, 58:69
 Medoff, D.R., 57:75, 58:53, 59:221
 Meesters, Y., 57:223
 Meltzer, H.Y., 58:89, 58:217
 Mercier, C., 60:205
 Miewald, J.M., 57:91, 59:203
 Miller, M.D., 56:17, 59:65
 Millet, P., 60:101
 Minges, J., 59:7
 Mintz, J., 57:155
 Mintz, L.I., 57:155
 Mirow, A., 58:23
 Mitropoulou, V., 57:109, 59:127, 60:49
 Modai, I., 57:193
 Mohs, R.C., 57:109, 58:181, 60:49
 Mokrani, M.-C., 60:23
 Möller, H.-J., 58:107
 Montrose, D.M., 57:91, 59:203
 Moore, T.C., 56:101
 Moran, M.J., 59:221
 Moreau, J.-L., 57:181
 Morel, C., 56:245

Morris, L., 60:167
 Morrison, R.L., 56:121
 Moss, H.B., 59:35
 Mueser, K.T., 56:121, 57:141, 59:213
 Müller, H., 58:107
 Mulsant, B.H., 60:117
 Murphy, D.G.M., 57:119
 Myers, F., 59:151
 Myslobodsky, M.S., 58:259

Nasrallah, H.A., 57:57, 57:83
 Naukkarinen, H., 58:145
 Nelson, E.C., 58:117
 Nerenberg, J., 59:171
 Nevitt, J., 57:75
 Newsom, J.T., 59:65
 Nisenson, L., 56:25
 Noorthoorn, E., 56:299
 Northcutt, C., 56:59
 Noyes, R., Jr., 57:1, 60:185

O'Brien, J., 57:131
 O'Callaghan, E., 59:119
 Oguz, H., 59:165
 Oomen, H.A.P.C., 58:83
 Oren, D.A., 59:151
 Orsulak, P.J., 60:41
 Osgood, G., 57:131
 Otto, M., 56:81
 Ozaki, N., 59:151

Panchalingam, K.S., 57:91
 Panerai, A.E., 59:43, 59:51
 Panksepp, J., 58:191
 Paradis, C.F., 56:17
 Parker, J.D.A., 58:139
 Parrella, M., 60:87
 Pasternak, R., 60:117
 Patralia, A., 56:295
 Pazzaglia, P.J., 57:259
 Peiper, S.C., 59:197
 Peirone, A., 59:43, 59:51
 Penn, D.L., 59:213
 Pepple, J.R., 56:135
 Peralta, V., 58:45, 58:227
 Perel, J.M., 56:17
 Perez, E., 60:1
 Perl, M., 58:13
 Perna, G., 57:267, 59:43, 59:51
 Perry, S.W., 59:245
 Peterson, E., 58:1
 Petit, M., 59:1, 59:25
 Pettegrew, J.W., 57:91
 Pettigrew, G., 56:237, 58:69
 Petty, F., 59:127, 60:41
 Pfefferbaum, A., 60:125
 Pigache, R.M., 60:155

Piketty, M.L., 57:41
 Plumet, M.-H., 58:191
 Pohl, R., 56:289
 Poirier, M.-F., 57:41
 Ponds, R., 56:299
 Post, R.M., 57:259
 Powchik, P., 60:87
 Preußler, 58:107
 Priebe, S., 58:77
 Prigerson, H.G., 59:65

Raeburn, S., 58:13
 Ragland, J.D., 60:135
 Raine, A., 56:71, 57:241
 Räisänen, M., 58:145
 Ramesh, C., 56:289
 Randall, P., 59:97
 Rao, M.L., 57:21
 Rapaport, M., 58:99
 Rapisarda, V., 56:295
 Rapoport, J.L., 60:67
 Rappe, S.M., 56:205
 Ravizza, L., 57:49
 Recasens, C., 58:191
 Rechlin, T., 56:279
 Reichelt, K.L., 58:171
 Reist, C., 57:197, 57:275, 59:189, 60:177
 Rémi-Bouissière, P., 57:41
 Rennie, C., 56:229, 56:237, 58:69
 Reynolds, C.F. III, 56:17, 57:91, 59:65, 59:203
 Rice, J., 56:221
 Richter, R., 58:23
 Rifai, A.H., 56:17
 Riordan, H., 60:167
 Risch, S.C., 58:23
 Ritzl, E.K., 57:75
 Roberts, C.R., 58:237
 Rochet, T., 60:205
 Roemer, R.A., 58:247
 Röhricht, F., 58:77
 Rommelspacher, H., 56:81
 Röschke, J., 56:257
 Roseman, C., 57:251
 Rosenthal, N.E., 59:151
 Ross, D.E., 58:53, 59:221
 Rossiter, E.M., 58:13
 Rotter, M., 57:109
 Rubin, S.A., 56:33
 Rubinow, D., 57:259
 Rubinson, E., 60:191
 Ruiz, J., 59:145
 Rush, A.J., 60:41
 Rusinek, H., 60:91
 Ryan, T.M., 58:181

Sacerdote, P., 59:43, 59:51
 Samolyk, D., 59:1

Samson, J.A., 56:25
 Saoud, J.B., 58:161
 Sarova-Pinchas, I., 58:177
 Sayers, S.L., 56:121
 Scarone, S., 58:37
 Scarvalone, P.A., 59:245
 Schaltenbrand, N., 60:23
 Schapiro, M.B., 57:119
 Scharpé, S., 58:217
 Schild, K., 60:199
 Schildkraut, J.J., 56:25
 Schmeidler, J., 58:181
 Schmidtke, A., 59:17
 Schneider, J.A., 58:13
 Schott, K., 59:251
 Schultz, L., 58:1
 Schwartz, P.J., 59:151
 Scott, T.M., 59:97
 Seidman, L.J., 56:135
 Sevush, S., 59:145
 Shapleske, J., 56:183
 Sheline, Y.I., 58:117
 Sheppard, N.P., 59:119
 Siever, L.J., 57:109, 59:127, 60:49
 Sikora, J., 59:161
 Silverman, J., 57:109, 59:127
 Sim, C.-B., 57:65
 Simeon, D., 58:161
 Simkowitz, P., 60:91
 Singer, J., 58:259
 Smeenk, R.J.T., 58:83
 Smeraldi, E., 58:265
 Smith, G., 60:91
 Sofuooglu, S., 59:165
 Sokolski, K.N., 57:197
 Spaulding, W., 59:213
 Spielman, L.A., 59:245
 Srinivasan, K., 56:289, 60:77
 Srisurapanont, M., 60:33
 Stack, J.A., 56:17
 Stein, D.J., 58:161
 Stein, M.A., 57:13
 Stein, M.B., 59:183
 Stern, M., 58:259
 Stöber, G., 59:17
 Strakowski, S.M., 57:209
 Strelbel, B., 57:21
 Sturm, Y., 58:107
 Stygall, J., 56:71
 Sullivan, E.V., 60:125
 Summerfelt, A., 56:33
 Sunderland, T., 57:259
 Sutton, L., 58:99
 Swedo, S.E., 60:67
 Sweet, R.A., 60:117

Tabuteau, F., 58:191

Tagliavini, P., 58:153
 Tamminga, C.A., 57:75, 58:53
 Tang, S.W., 57:275, 59:189, 60:177
 Teichberg, D., 57:119
 Teigland-Gjerstad, B., 58:171
 Telch, C.F., 58:13
 Teng, C.T., 56:11
 Terra, J.-L., 60:205
 Thaker, G.K., 58:53, 59:221
 Thibaut, F., 59:25, 59:1
 Thomson, C., 57:241
 Thornes, K., 56:1
 Tierney, A.M., 56:121
 Tompson, M.C., 57:155
 Torello, M.W., 57:57, 57:83
 Trestman, R.L., 57:109, 59:127
 Trivedi, M., 60:41
 True, J.E., 56:101
 Tsai, S.-J., 57:65
 Tseng, Y.-T., 57:101
 Tsuang, M.T., 56:135
 Tucker, H.A., 56:221
 Tuckwell, H.C., 59:239
 Tueting, P.A., 57:83

Unis, A.S., 57:13

Valdivieso, S., 60:23
 Valevski, A., 57:193
 van Engeland, H., 58:203
 Vanelle, J.-M., 57:41
 van Kammen, D.P., 60:11
 Vanyukov, M.M., 59:35
 Velligan, D.I., 56:101
 Vieira, A.H.G., 56:11
 Viret, J., 59:255
 Virkkunen, M., 58:145
 Vogler, G.P., 56:213
 Volavka, J., 59:161
 Volkow, N.D., 60:91, 60:167
 Volz, H.-P., 58:107
 Vu, R., 57:275, 59:189

Wade, J.H., 56:121
 Waller-Perotte, D., 58:191
 Waltrip, R.W. II, 56:33
 Wang, G.-J., 60:167
 Weijnen, F.G., 58:203
 Weinberger, D.R., 56:53, 56:155
 Weis, M., 56:279
 Weiss, K.M., 60:147
 Weissman, M.M., 57:169
 Weizman, A., 57:193
 Wekking, E.M., 58:83
 West, J., 56:205
 White, L., 60:87
 Wieneke, M., 60:167

Wildenauer, D., 59:7
Willemsen-Swinkels, S.H.N., 58:203
Wolf, J., 59:171
Wolf, A.P., 60:91
Wolfe, V., 56:59
Wolkin, A., 60:91
Woodman, C., 57:1
Wormstall, H., 59:251
Wu, S., 57:57, 57:83

Yang, Y.-C., 57:65
Yao, J.K., 60:11
Yatham, L.N., 60:33
Yeragani, V.K., 56:289, 60:77
Young, L.T., 58:139
Yu, L.M., 59:35

Zahn, T.P., 60:67
Zaimovic, A., 58:153
Zarcone, V.P., Jr., 60:125
Zemishlany, Z., 57:109
Zhang-Wong, J., 59:109
Zill, P., 59:7
Zis, A.P., 60:33
Zubenko, G.S., 60:117





Subject index for 1995

Adrenocorticotropic hormone

affective disorder, cortisol, 59:157

Affective disorder

age, cognition, 60:87

age disorientation, bipolar subtype, 60:87

age disorientation, cognition, 60:87

age disorientation, late-life depression, 60:87

age, interpersonal psychotherapy, 56:17

age, magnetic resonance imaging, 60:117

age, treatment outcome, 56:17

age, white matter hyperintensity, 60:117

anhedonia, bipolar subtype, 56:163

anhedonia, endogenomorphic subtype, 60:57

anhedonia, laterality, 56:163

anhedonia, skin conductance, 56:163

anticholinergic agent, sleep, rapid eye movement, 58:99

antidepressant effect, *S*-adenosyl-L-methionine, 56:295

anxiety disorder, comorbidity, 59:57

Arden ratio, circadian rhythm, 57:197

Arden ratio, sleep, 57:197

Arden ratio, sleep deprivation, 57:197

atypical depression, cortisol, 60:191

atypical depression, desipramine, 60:191

atypical depression, norepinephrine, 60:191

biperiden, sleep, rapid eye movement, 58:99

bipolar subtype, age disorientation, 60:87

bipolar subtype, anhedonia, 56:163

bipolar subtype, calcium pump, 59:197

bipolar subtype, cerebrospinal fluid protein, 57:259

bipolar subtype, chromosome 18, 59:7

bipolar subtype, cognition, 60:87

bipolar subtype, dopamine- β -hydroxylase, 59:165

bipolar subtype, expressed emotion, 56:299

bipolar subtype, family therapy, 56:299

bipolar subtype, genetics, 59:7

bipolar subtype, harm avoidance, 57:209, 58:139

bipolar subtype, ion channels, 59:197

bipolar subtype, laterality, 56:163, 57:279

bipolar subtype, linkage analysis, 59:7

bipolar subtype, lithium, 59:165

bipolar subtype, lymphoblast cells, 59:197

bipolar subtype, monoamine oxidase, 59:165

bipolar subtype, motor activity, 57:279

bipolar subtype, negative symptoms, 56:145

bipolar subtype, novelty seeking, 58:139

bipolar subtype, pain, 56:173

bipolar subtype, personality, 57:209

bipolar subtype, psychoeducation, 56:299

bipolar subtype, sex, 57:259

bipolar subtype, signal detection, 56:173

bipolar subtype, skin conductance, 56:163

bipolar subtype, sodium pump, 59:197

bipolar subtype, stimulus intensity, 56:173

bipolar subtype, suicidality, 59:57

bipolar subtype, transmembrane potential, 59:197

bipolar subtype, Tridimensional Personality Questionnaire, 57:209, 58:139

bipolar subtype vs. unipolar subtype, 58:139, 59:57

brofaromine, late-life depression, 58:107

brofaromine, response prediction, 58:107

calcium pump, bipolar subtype, 59:197

calcium pump, ion channels, 59:197

calcium pump, lymphoblast cells, 59:197

calcium pump, transmembrane potential, 59:197

carbohydrate craving, circannual rhythm, 59:171

carbohydrate craving, light therapy, 59:171

carbohydrate craving, seasonal affective disorder, 59:171

carbohydrate craving, taste detection, 59:171

cerebrospinal fluid protein, bipolar subtype, 57:259

cerebrospinal fluid protein, sex, 57:259

chromosome 18, bipolar subtype, 59:7

chromosome 18, linkage analysis, 59:7

circadian rhythm, Arden ratio, 57:197

circadian rhythm, electrooculography, 57:197

circadian rhythm, light therapy, 56:221

circadian rhythm, melatonin, 56:221

circadian rhythm, photoperiod, 60:199

circadian rhythm, seasonal affective disorder, 56:221

circadian rhythm, sleep, sleep deprivation, 57:197

circadian rhythm, violence, 60:199

circadian rhythm, visual adaptation, 57:197

circannual rhythm, carbohydrate craving, 59:171

circannual rhythm, electrooculography ratio, 59:151

circannual rhythm, ethology, 57:223

circannual rhythm, light therapy, 56:11, 56:221, 57:223, 59:171

circannual rhythm, melatonin, 56:221

circannual rhythm, photoperiod, 60:199

circannual rhythm, retina, 59:151
 circannual rhythm, seasonal affective disorder, 56:11, 56:221, 57:223, 59:151, 59:171
 circannual rhythm, Southern Hemisphere, 56:11
 circannual rhythm, taste detection, 59:171
 circannual rhythm, violence, 60:199
 clonidine, growth hormone, 60:23
 cognition, age disorientation, 60:87
 comorbidity, anxiety disorder, 59:57
 comorbidity, epidemiology, 59:57
 comorbidity, panic disorder, 59:57
 computed tomography, cortisol, 59:157
 cortisol, atypical depression, 60:191
 cortisol, computed tomography, 59:157
 cortisol, desipramine, 60:191
 cortisol, dexamethasone, 60:23
 delirium, amitriptyline, 56:279
 desipramine, atypical depression, 60:191
 desipramine, norepinephrine, 60:191
 dexamethasone, cortisol, 60:23
 diagnosis, outcome, 59:109
 dopamine- β -hydroxylase, monoamine oxidase, 59:165
 elderly patients, magnetic resonance imaging, 60:117
 elderly patients, white matter hyperintensity, 60:117
 electroencephalography, period analysis, 56:245
 electroencephalography, power spectral-analysis, 56:245
 electroencephalography, sleep, 56:245
 electrooculography, Arden ratio, 57:197
 electrooculography, circadian rhythm, 57:197, 59:151
 electrooculography, retina, 59:151
 electrooculography, seasonal affective disorder, 59:151
 electrooculography, sleep, sleep deprivation, 57:197
 electrooculography, visual adaptation, 57:197
 endogenomorphic subtype, anhedonia, 60:57
 epidemiology, comorbidity, 59:57
 epidemiology, genetics, 57:169
 epidemiology, sex, 58:1
 epidemiology, suicidality, 59:57
 ethology, circannual rhythm, 57:223
 ethology, light therapy, 57:223
 ethology, seasonal affective disorder, 57:223
 expressed emotion, bipolar subtype, 56:299
 expressed emotion, family therapy, 56:299
 expressed emotion, psychoeducation, 56:299
 family therapy, bipolar subtype, 56:299
 family therapy, expressed emotion, 56:299
 family therapy, psychoeducation, 56:299
 Family History Screen for Epidemiologic Studies, genetics, 57:169
 fluoxetine, mania, 58:217
 fluoxetine, prolyl endopeptidase, 58:217
 fluoxetine, valproate, 58:217
 genetics, bipolar subtype, 59:7
 genetics, chromosome 18, 59:7
 genetics, Family History Screen for Epidemiologic Studies, 57:169
 genetics, linkage analysis, 59:7
 growth hormone, clonidine, 60:23
 harm avoidance, bipolar subtype, 57:209, 58:139
 harm avoidance, Tridimensional Personality Questionnaire, 57:209, 58:139
 harm avoidance, unipolar subtype, 58:139
 heart rate, amitriptyline, 56:279
 heart rate, delirium, 56:279
 imipramine, late-life depression, 58:107
 imipramine, pharmacokinetics, 59:189
 imipramine, response prediction, 58:107
 interpersonal psychotherapy, late-life depression, 56:17
 interpersonal psychotherapy, nortriptyline, 56:17
 interpersonal psychotherapy, recruitment method, 56:17
 interpersonal psychotherapy, treatment outcome, 56:17
 ion channels, bipolar subtype, 59:197
 ion channels, calcium pump, 59:197
 ion channels, lymphoblast cells, 59:197
 ion channels, sodium pump, 59:197
 ion channels, transmembrane potential, 59:197
 late-life depression, age disorientation, 60:87
 late-life depression, brofaromine, 58:107
 late-life depression, cognition, 60:87
 late-life depression, imipramine, 58:107
 late-life depression, interpersonal psychotherapy, 56:17
 late-life depression, magnetic resonance imaging, 60:117
 late-life depression, monoamine oxidase inhibitor, 58:107
 late-life depression, nortriptyline, 56:17
 late-life depression, recruitment method, 56:17
 late-life depression, response prediction, 58:107
 late-life depression, treatment outcome, 56:17
 late-life depression, white matter hyperintensity, 60:117
 laterality, bipolar subtype, 56:163, 57:279
 laterality, motor activity, 57:279
 laterality, skin conductance, 56:163
 light therapy, carbohydrate craving, 59:171
 light therapy, circadian rhythm, 56:221
 light therapy, circannual rhythm, 56:11, 56:221, 57:223, 59:171
 light therapy, melatonin, 56:221
 light therapy, seasonal affective disorder, 56:11, 56:221, 57:223, 59:171
 linkage analysis, bipolar subtype, 59:7
 linkage analysis, chromosome 18, 59:7
 lithium, bipolar subtype, 59:165
 lymphoblast cells, bipolar subtype, 59:197
 lymphoblast cells, calcium pump, 59:197
 lymphoblast cells, ion channels, 59:197
 lymphoblast cells, sodium pump, 59:197
 lymphoblast cells, transmembrane potential, 59:197
 magnetic resonance imaging, age, 60:117
 magnetic resonance imaging, late-life depression, 60:117
 magnetic resonance imaging, white matter hyperintensity, 60:117
 mania, fluoxetine, 58:217
 mania, peptides, 58:217
 mania, prolyl endopeptidase, 58:217
 mania, valproate, 58:217
 melatonin, circadian rhythm, 56:221

melatonin, circannual rhythm, 56:221
 melatonin, light therapy, 56:221
 melatonin, seasonal affective disorder, 56:221
 monoamine oxidase, bipolar subtype, 59:165
 monoamine oxidase inhibitor, late-life depression, 58:107
 monoamine oxidase inhibitor, response prediction, 58:107
 monoamine oxidase, platelets, 59:165
 motor activity, bipolar subtype, 57:279
 motor activity, laterality, 57:279
 negative symptoms, transitory nature, 56:145
 norepinephrine, atypical depression, 60:191
 norepinephrine, desipramine, 60:191
 nortriptyline, age, 56:17
 nortriptyline, interpersonal psychotherapy, 56:17
 nortriptyline, late-life depression, 56:17
 nortriptyline, treatment outcome, 56:17
 novelty seeking, bipolar subtype, 58:139
 novelty seeking, Tridimensional Personality Questionnaire, 58:139
 novelty seeking, unipolar subtype, 58:139
 ondansetron, prolactin, 60:33
 ondansetron, serotonin, 60:33
 outcome, diagnosis, 59:109
 pain, bipolar subtype, 56:173
 pain, signal detection, 56:173
 pain, stimulus intensity, 56:173
 paroxetine binding, platelet, 58:117
 paroxetine, serotonin, 58:117, 59:189
 peptides, mania, 58:217
 personality, bipolar subtype, 57:209
 pharmacokinetics, imipramine, 59:189
 polysomnography, period analysis, 56:245
 polysomnography, power spectral analysis, 56:245
 prognosis, presence of negative symptoms in first episode, 56:145
 prolactin, ondansetron, 60:33
 prolyl endopeptidase, mania, 58:217
 protein, cerebrospinal fluid, 57:259
 protein, sex, 57:259
 psychoeducation, bipolar subtype, 56:299
 psychoeducation, expressed emotion, 56:299
 psychoeducation, family therapy, 56:299
 rapid eye movement, anticholinergic agent, 58:99
 rapid eye movement, biperiden, 58:99
 response prediction, brofaromine, 58:107
 response prediction, imipramine, 58:107
 response prediction, late-life depression, 58:107
 response prediction, monoamine oxidase inhibitor, 58:107
 retina, circannual rhythm, 59:151
 retina, electrooculography, 59:151
 retina, seasonal affective disorder, 59:151
 S-adenosyl-L-methionine, antidepressant effect, 56:295
 seasonal affective disorder, carbohydrate craving, 59:171
 seasonal affective disorder, circadian rhythm, 56:221
 seasonal affective disorder, circannual rhythm, 56:11, 56:221, 57:223, 59:151, 59:171
 seasonal affective disorder, electrooculography, 59:151
 seasonal affective disorder, ethology, 57:223
 seasonal affective disorder, light therapy, 56:221, 57:223, 59:171
 seasonal affective disorder, melatonin, 56:221
 seasonal affective disorder, retina, 59:151
 seasonal affective disorder, Southern Hemisphere, 56:11
 seasonal affective disorder, taste detection, 59:171
 serotonin, ondansetron, 60:33
 serotonin, paroxetine, 58:117, 59:189
 serotonin, platelet, 58:117
 serotonin, prolactin, 60:33
 sex, bipolar subtype, 57:259
 sex, epidemiology, 58:1
 sex, protein, 57:259
 signal detection, bipolar subtype, 56:173
 signal detection, pain, 56:173
 signal detection, stimulus intensity, 56:173
 skin conductance, anhedonia, 56:163
 skin conductance, bipolar subtype, 56:163
 skin conductance, laterality, 56:163
 sleep, anticholinergic agent, 58:99
 sleep, biperiden, 58:99
 sleep, circadian rhythm, 57:197
 sleep deprivation, Arden ratio, 57:197
 sleep deprivation, circadian rhythm, 57:197
 sleep deprivation, electrooculography, 57:197
 sleep deprivation, visual adaptation, 57:197
 sleep, electroencephalography, 56:245
 sleep, electrooculography, 57:197
 sleep, period analysis, 56:245
 sleep, polysomnography, 56:245
 sleep, power spectral analysis, 56:245
 sleep, rapid eye movement, 58:99
 sleep, visual adaptation, 57:197
 sodium pump, bipolar subtype, 59:197
 sodium pump, ion channels, 59:197
 sodium pump, lymphoblast cells, 59:197
 sodium pump, transmembrane potential, 59:197
 stimulus intensity, pain, 56:173
 stimulus intensity, signal detection, 56:173
 suicidality, bipolar subtype, 59:57
 suicidality, epidemiology, 59:57
 suicidality, unipolar subtype, 59:57
 taste detection, carbohydrate craving, 59:171
 taste detection, circannual rhythm, 59:171
 taste detection, light therapy, 59:171
 taste detection, seasonal affective disorder, 59:171
 thyroid hormones, 57:41, 57:41
 thyroid-stimulating hormone, thyrotropin-releasing hormone, 57:41
 thyrotropin-releasing hormone, thyroid-stimulating hormone, 57:41
 transmembrane potential, bipolar subtype, 59:197
 transmembrane potential, calcium pump, 59:197
 transmembrane potential, ion channels, 59:197
 transmembrane potential, lymphoblast cells, 59:197
 transmembrane potential, sodium pump, 59:197
 treatment outcome, age, 56:17
 treatment outcome, interpersonal psychotherapy, 56:17
 treatment outcome, late-life depression, 56:17

treatment outcome, nortriptyline, 56:17
 Tridimensional Personality Questionnaire, bipolar subtype, 57:209, 58:139
 Tridimensional Personality Questionnaire, harm avoidance, 57:209, 58:139
 Tridimensional Personality Questionnaire, novelty seeking, 58:139
 Tridimensional Personality Questionnaire, unipolar subtype, 58:139
 unipolar subtype, epidemiology, 59:57
 unipolar subtype, harm avoidance, 58:139
 unipolar subtype, novelty seeking, 58:139
 unipolar subtype, suicidality, 59:57
 unipolar subtype, Tridimensional Personality Questionnaire, 58:139
 unipolar subtype vs. bipolar subtype, 58:139, 59:57
 valproate, mania, 58:217
 valproate, prolyl endopeptidase, 58:217
 violence, circadian rhythm, 60:199
 violence, circannual rhythm, 60:199
 violence, photoperiod, 60:199
 visual adaptation, Arden ratio, 57:197
 visual adaptation, circadian rhythm, 57:197
 visual adaptation, electrooculography, 57:197
 white matter hyperintensity, age, 60:117
 white matter hyperintensity, late-life depression, 60:117
 white matter hyperintensity, magnetic resonance imaging, 60:117

Age

affective disorder, age disorientation, 60:87
 affective disorder, cognition, 60:87
 affective disorder, interpersonal psychotherapy, 56:17
 affective disorder, magnetic resonance imaging, 60:117
 affective disorder, schizophrenia, 60:117
 affective disorder, treatment outcome, 56:17
 affective disorder, white matter hyperintensity, 60:117
 age disorientation, affective disorder, 60:87
 age disorientation, bipolar subtype, 60:87
 age disorientation, cognition, 60:87
 age disorientation, late-life depression, 60:87
 Alzheimer's Disease, brain volume, 57:119
 Alzheimer's Disease, magnetic resonance imaging, 57:119
 Alzheimer's Disease, sex, 57:119
 Alzheimer's Disease, temporal lobe, 57:119
 bipolar affective disorder, age disorientation, 60:87
 bipolar affective disorder, cognition, 60:87
 brain volume, Alzheimer's Disease, 57:119
 brain volume, dementia, 57:119
 brain volume, magnetic resonance imaging, 57:119
 brain volume, temporal lobe, 57:119
 cognition, age disorientation, 60:87
 cognition, late-life depression, 60:87
 dementia, brain volume, 57:119
 dementia, magnetic resonance imaging, 57:119
 dementia, temporal lobe, 57:119
 interpersonal psychotherapy, late-life depression, 56:17
 interpersonal psychotherapy, treatment outcome, 56:17

late-life depression, magnetic resonance imaging, 60:117
 late-life depression, white matter hyperintensity, 60:117
 late-life depression, interpersonal psychotherapy, 56:17
 late-life depression, nortriptyline, 56:17
 late-life depression, treatment outcome, 56:17
 late-life depression, age disorientation, 60:87
 late-life depression, cognition, 60:87
 magnetic resonance imaging, affective disorder, 60:117
 magnetic resonance imaging, Alzheimer's Disease, 57:119
 magnetic resonance imaging, brain volume, 57:119
 magnetic resonance imaging, dementia, 57:119
 magnetic resonance imaging, elderly patients, 60:117
 magnetic resonance imaging, late-life depression, 60:117
 magnetic resonance imaging, schizophrenia, 60:117
 magnetic resonance imaging, temporal lobe, 57:119
 magnetic resonance imaging, white matter hyperintensity, 60:117
 nortriptyline, interpersonal psychotherapy, 56:17
 nortriptyline, late-life depression, 56:17
 nortriptyline, treatment outcome, 56:17
 schizophrenia, elderly patients, 60:117
 schizophrenia, magnetic resonance imaging, 60:117
 schizophrenia, white matter hyperintensity, 60:117
 sex, Alzheimer's Disease, 57:119
 sex, dementia, 57:119
 temporal lobe, Alzheimer's Disease, 57:119
 temporal lobe, brain volume, 57:119
 temporal lobe, dementia, 57:119
 temporal lobe, magnetic resonance imaging, 57:119
 treatment outcome, geriatric psychiatry, 56:17
 treatment outcome, late-life depression, 56:17
 white matter hyperintensity, late-life depression, 60:117
 white matter hyperintensity, magnetic resonance imaging, 60:117
 white matter hyperintensity, schizophrenia, 60:117

Agoraphobia. *See Anxiety disorder; Panic disorder*

Aggression

anger attacks, anorexia, bulimia, 56:205
 anorexia, anger attacks, 56:205
 bulimia, anger attacks, 56:205
 conduct disorder, dinucleotide repeat polymorphism, 59:35
 conduct disorder, genetics, 59:35
 conduct disorder, monoamine oxidase, 59:35
 conduct disorder, personality, 59:35
 conduct disorder, polymerase chain reaction, 59:35
 dinucleotide repeat polymorphism, conduct disorder, 59:35
 dinucleotide repeat polymorphism, genetics, 59:35
 dinucleotide repeat polymorphism, monoamine oxidase, 59:35
 dinucleotide repeat polymorphism, personality, 59:35
 dinucleotide repeat polymorphism, polymerase chain reaction, 59:35
 eating disorder, anger attacks, 56:205
 genetics, conduct disorder, 59:35
 genetics, dinucleotide repeat polymorphism, 59:35
 genetics, monoamine oxidase, 59:35

genetics, personality, 59:35
 genetics, polymerase chain reaction, 59:35
 monoamine oxidase, conduct disorder, 59:35
 monoamine oxidase, dinucleotide repeat polymorphism, 59:35
 monoamine oxidase, genetics, 59:35
 monoamine oxidase, personality, 59:35
 monoamine oxidase, polymerase chain reaction, 59:35
 personality, dinucleotide repeat polymorphism, 59:35
 personality, genetics, 59:35
 personality, monoamine oxidase, 59:35
 personality, polymerase chain reaction, 59:35
 polymerase chain reaction, dinucleotide repeat polymorphism, 59:35
 polymerase chain reaction, monoamine oxidase, 59:35
 polymerase chain reaction, personality, 59:35

Alcohol dependence
 abstinence, blood pressure, 59:137
 abstinence, cortisol, 56:81
 abstinence, γ -aminobutyric acid, 59:137
 abstinence, heart rate, 59:137
 abstinence, hypothalamic-pituitary-gonadal axis, 56:81
 abstinence, liver function, 59:137
 abstinence, prolactin, 56:81
 anxiety, abstinence, 59:137
 anxiety, blood pressure, 59:137
 anxiety, γ -aminobutyric acid, 59:137
 anxiety, heart rate, 59:137
 anxiety, liver function, 59:137
 blood pressure, abstinence, 59:137
 blood pressure, anxiety, 59:137
 blood pressure, γ -aminobutyric acid, 59:137
 calcium, intracellular, 57:275
 calcium, serotonin, 57:275
 cortisol, abstinence, 56:81
 γ -aminobutyric acid, abstinence, 59:137
 γ -aminobutyric acid, anxiety, 59:137
 γ -aminobutyric acid, blood pressure, 59:137
 γ -aminobutyric acid, heart rate, 59:137
 γ -aminobutyric acid, liver function, 59:137
 heart rate, abstinence, 59:137
 heart rate, anxiety, 59:137
 heart rate, γ -aminobutyric acid, 59:137
 hypothalamic-pituitary-gonadal axis, abstinence, 56:81
 liver function, abstinence, 59:137
 prolactin, abstinence, 56:81
 serotonin, intracellular calcium, 57:275

Alzheimer's Disease
 autoantibody reactivity, dementia, 59:251
 brain volume, discriminant analysis, 57:119
 brain volume, magnetic resonance imaging, 57:119
 brain volume, sex, 57:119
 brain volume, temporal lobe, 57:119
 cognition, deprenyl, 58:181
 cognition, monoamine oxidase inhibitor, 58:181
 cognition, physostigmine, 58:181
 deprenyl, cognition, 58:181

discriminant analysis, brain volume, 57:119
 discriminant analysis, magnetic resonance imaging, 57:119
 evoked potentials, genetics, 57:57
 evoked potentials, oddball paradigm, 57:57
 evoked potentials, risk study, 57:57
 genetics, evoked potentials, 57:57
 genetics, risk study, 57:57
 immunology, autoantibody reactivity, 59:251
 magnetic resonance imaging, brain volume, 57:119
 magnetic resonance imaging, discriminant analysis, 57:119
 magnetic resonance imaging, sex, 57:119
 magnetic resonance imaging, temporal lobe, 57:119
 monoamine oxidase inhibitor, cognition, 58:181
 neuroleptic effect, brain volume, 57:119
 neuroleptic effect, magnetic resonance imaging, 57:119
 physostigmine, cognition, 58:181
 risk study, dementia, 57:57
 risk study, evoked potentials, 57:57
 risk study, genetics, 57:57
 serotonin, dementia, 59:145
 serotonin, platelets, 59:145
 sex, age, 57:119
 sex, brain volume, 57:119
 sex, neuroleptic effect, 57:119
 sex, temporal lobe, 57:119
 temporal lobe, age, 57:119
 temporal lobe, brain volume, 57:119
 temporal lobe, magnetic resonance imaging, 57:119
 temporal lobe, neuroleptic effect, 57:119
 temporal lobe, sex, 57:119

Amphetamine
 animal study, 2-deoxyglucose, 57:65
 animal study, local cerebral glucose, 57:65
 animal study, rat, 57:65

Anger attacks
 aggression, anorexia, bulimia, 56:205
 anorexia, aggression, 56:205
 bulimia, aggression, 56:205
 eating disorder, aggression, 56:205

Anhedonia
 affective disorder, bipolar subtype, 56:163
 affective disorder, laterality, 56:163
 affective disorder, skin conductance, 56:163
 bipolar affective disorder, laterality, 56:163
 bipolar affective disorder, skin conductance, 56:163
 laterality, bipolar affective disorder, 56:163
 laterality, schizoaffective disorder, 56:163
 laterality, schizophrenia, 56:163
 laterality, skin conductance, 56:163
 schizoaffective disorder, laterality, 56:163
 schizoaffective disorder, skin conductance, 56:163
 schizophrenia, laterality, 56:163
 schizophrenia, skin conductance, 56:163
 skin conductance, bipolar affective disorder, 56:163
 skin conductance, laterality, 56:163

skin conductance, schizoaffective disorder, 56:163
 skin conductance, schizophrenia, 56:163

Animal models and studies

alprazolam, anxiety disorder, 57:181
 alprazolam, dorsal periaqueductal gray matter, 57:181
 alprazolam, intracerebral stimulation, 57:181
 alprazolam, panic disorder, 57:181
 amphetamine, 2-deoxyglucose, 57:65
 amphetamine, local cerebral glucose, 57:65
 anxiety disorder, rat model, 57:181
 apomorphine, dopamine, 58:165
 apomorphine, phospholipase A2, 58:165
 carbamazepine, circadian rhythm, hamster, 57:215
 circadian rhythm, carbamazepine, hamster, 57:215
 circadian rhythm, lithium, 57:215
 circadian rhythm, valproate, 57:215
 circadian rhythm, verapamil, 57:215
 clonazepam, anxiety disorder, 57:181
 clonazepam, panic disorder, 57:181
 clonazepam, rat, 57:181
 clonazepam, yohimbine, 57:181
 2-deoxyglucose, amphetamine, rat, 57:65
 dopamine, apomorphine, rat, 58:165
 dopamine, phospholipase A2, rat, 58:165
 dorsal periaqueductal gray matter, intracerebral stimulation, 57:181
 dorsal periaqueductal gray matter, rat, 57:181
 hamster, carbamazepine, 57:215
 hamster, circadian rhythm, 57:215
 hamster, lithium, 57:215
 hamster, valproate, 57:215
 hamster, verapamil, 57:215
 intracerebral stimulation, dorsal periaqueductal gray matter, rat, 57:181
 lithium, circadian rhythm, hamster, 57:215
 local cerebral glucose, amphetamine, rat, 57:65
 panic-anxiety disorder, rat model, 57:181
 phospholipase A2, apomorphine, rat, 58:165
 phospholipase A2, dopamine, rat, 58:165
 rat, alprazolam, 57:181
 rat, amphetamine, 57:65
 rat, apomorphine, 58:165
 rat, clonazepam, 57:181
 rat, 2-deoxyglucose, 57:65
 rat, dopamine, 58:165
 rat, dorsal periaqueductal gray matter, 57:181
 rat, intracerebral stimulation, 57:181
 rat, local cerebral glucose, 57:65
 rat, phospholipase A2, 58:165
 rat, yohimbine, 57:181
 valproate, circadian rhythm, hamster, 57:215
 verapamil, circadian rhythm, hamster, 57:215
 yohimbine, anxiety-panic model, rat, 57:181

Anorexia nervosa. See Eating disorder

Anticardiolipin antibody

dementia, immunology, 58:83
 dementia, vascular signs, 58:83
 immunology, dementia, 58:83
 immunology, vascular signs, 58:83
 vascular signs, dementia, 58:83
 vascular signs, immunology, 58:83

Anxiety

human immunodeficiency virus, Structured Clinical Interview for DSM-III-R, 59:245
 Structured Clinical Interview for DSM-III-R, human immunodeficiency virus, 59:245
 visual analogue scale, human immunodeficiency virus, 59:245
 visual analogue scale, Structured Clinical Interview for DSM-III-R, 59:245

Anxiety disorder. See also Obsessive-compulsive disorder; Panic disorder; Posttraumatic stress disorder; Social phobia

Acute Panic Inventory, lactate, 58:127
 Acute Panic Inventory, panic attacks, 58:127
 agoraphobia, carbon dioxide inhalation, 57:267
 agoraphobia, panic attacks, 57:267
 alprazolam, animal model of panic-anxiety, 57:181
 animal model, dorsal periaqueductal gray matter, rat, 57:181
 blood pressure, lactate-induced panic attacks, 58:127
 carbon dioxide inhalation, agoraphobia, 57:267
 carbon dioxide inhalation, panic attacks, 57:267
 clonazepam, animal model of panic-anxiety, 57:181
 diazepam, blood pressure, 58:127
 diazepam, lactate-induced panic attacks, 58:127
 epidemiology, genetics, 57:169
 epidemiology, sex, 58:1
 Family History Screen for Epidemiologic Studies, genetics, 57:169
 genetics, Family History Screen for Epidemiologic Studies, 57:169
 heart rate, isoproterenol, 56:289
 heart rate, spectral analysis, 56:289
 heart rate, sympathovagal ratio, 56:289
 5-hydroxyindoleacetic acid, serotonin, 57:1
 5-hydroxyindoleacetic acid, urinary measures, 57:1
 isoproterenol, heart rate, 56:289
 isoproterenol, panic disorder, 56:289
 isoproterenol, sympathovagal ratio, 56:289
 lactate infusion, Acute Panic Inventory, 58:127
 lactate infusion, blood pressure, 58:127
 lactate infusion, panic attacks, 58:127
 N-acetyl- β -glucosaminidase, anxiety, 60:185
 neuropeptide Y, norepinephrine, 59:183
 neuropeptide Y, stress, 59:183
 norepinephrine, panic disorder, 59:183
 norepinephrine, stress, 59:183
 norepinephrine, urinary measures, 57:1
 norepinephrine, vanillylmandelic acid, 57:1
 panic attacks, Acute Panic Inventory, 58:127

panic attacks, agoraphobia, 57:267
 panic attacks, blood pressure, 58:127
 panic attacks, carbon dioxide inhalation, 57:267
 panic attacks, diazepam, 58:127
 panic attacks, lactate infusion, 58:127
 peptides, panic disorder, 59:183
 peptides, social phobia, 59:183
 peptides, stress, 59:183
 Profile of Mood States, *N*-acetyl- β -glucomannidase, 60:185
 rat, panic-anxiety model, 57:181
 serotonin, 5-hydroxyindoleacetic acid, 57:1
 serotonin, urinary measures, 57:1
 sex, epidemiology, 58:1
 social phobia, neuropeptide Y, 59:183
 social phobia, norepinephrine, 59:183
 social phobia, stress, 59:183
 stress, neuropeptide Y, 59:183
 stress, norepinephrine, 59:183
 stress, peptides, 59:183
 sympathovagal ratio, isoproterenol, 56:289
 sympathovagal ratio, panic disorder, 56:289
 vanillylmandelic acid, norepinephrine, 57:1
 vanillylmandelic acid, urinary measures, 57:1
 yohimbine, animal model of panic-anxiety, 57:181

Apomorphine

dopamine, phospholipase A2, rat, 58:165
 phospholipase A2, dopamine, rat, 58:165

Arachidonic acid

phospholipids, schizophrenia, 60:11
 schizophrenia, phospholipids, 60:11

Attention. *See also Cognition; Neuropsychology*

Continuous Performance Test, distractibility, 57:131
 Continuous Performance Test, neuroleptic effects, 57:131
 Continuous Performance Test, schizophrenia, 57:131
 disorganized symptoms, heart rate, 57:241
 disorganized symptoms, schizoaffective disorder, 57:241
 disorganized symptoms, schizophrenia, 57:241
 evoked potentials, P300 component, 58:69
 evoked potentials, reaction time, 58:69
 evoked potentials, schizophrenia, 58:69
 heart rate, skin conductance, 57:241
 negative symptoms, schizoaffective disorder, 57:241
 negative symptoms, schizophrenia, 57:241
 neuroleptic effects, Continuous Performance Test, 57:131
 neuroleptic effects, distractibility, 57:131
 neuroleptic effects, schizophrenia, 57:131
 positive symptoms, schizoaffective disorder, 57:241
 positive symptoms, schizophrenia, 57:241
 reaction time, evoked potentials, 58:69
 reaction time, schizophrenia, 58:69
 schizoaffective disorder, disorganized symptoms, 57:241
 schizoaffective disorder, negative symptoms, 57:241
 schizoaffective disorder, positive symptoms, 57:241

schizophrenia, Continuous Performance Test, 57:131
 schizophrenia, disorganized symptoms, 57:241
 schizophrenia, distractibility, 57:131
 schizophrenia, evoked potentials, 58:69
 schizophrenia, negative symptoms, 57:241
 schizophrenia, neuroleptic effects, 57:131
 schizophrenia, positive symptoms, 57:241
 schizophrenia, reaction time, 58:69
 schizophrenia, social cue perception, 56:111
 schizophrenia, tone discrimination, 57:75
 skin conductance, heart rate, 57:241
 social cue perception, schizophrenia, 56:111
 tone discrimination, schizophrenia, 57:75

Attention deficit hyperactivity disorder

attention, neuropsychology, Stroop test, 56:59
 conduct disorder, genetics, 57:13
 conduct disorder, serotonin, 57:13
 genetics, conduct disorder, oppositional-defiant disorder, 57:13
 genetics, serotonin, 57:13
 neuropsychology, attention, 56:59
 oppositional-defiant disorder, genetics, 57:13
 oppositional-defiant disorder, serotonin, 57:13
 serotonin, conduct disorder, oppositional-defiant disorder, 57:13
 serotonin, genetics, 57:13
 Stroop test, attention, 56:59

Autism

β -endorphin, cortisol, 58:203
 cortisol, β -endorphin, 58:203
 naltrexone, β -endorphin, 58:191, 58:203
 naltrexone, cortisol, 58:203
 naltrexone, social behavior, 58:203
 naltrexone, treatment response, 58:191, 58:203
 social behavior, naltrexone, 58:203
 treatment response to naltrexone, 58:191, 58:203

Autonomic nervous system. *See Blood pressure; Heart rate; Skin conductance*

Baclofen

γ -aminobutyric acid, growth hormone, 60:41

Behavior therapy

agoraphobia, panic disorder, 56:1
 alcohol abuse, 56:1
 anxiety disorder, agoraphobia, 56:1
 obsessive-compulsive disorder, 56:1
 panic disorder, agoraphobia, 56:1
 personality disorder, 56:1

Bereavement

depression, factor analysis, 59:65
 depression, Inventory of Complicated Grief, 59:65
 factor analysis, depression, 59:65

factor analysis, Inventory of Complicated Grief, 59:65
 Inventory of Complicated Grief, depression, 59:65
 Inventory of Complicated Grief, factor analysis, 59:65

Beta-endorphin

amineptine, anorexia, 59:43
 amineptine, bulimia, 59:51
 anorexia, amineptine, 59:43
 anorexia, cholecystokinin-8, 59:43
 anorexia, eating disorder, 59:43
 anorexia, fluoxetine, 59:43
 anorexia, peptides, 59:43
 autism, naltrexone, 58:191, 58:203
 autism, social behavior, 58:203
 bulimia, amineptine, 59:51
 bulimia, cholecystokinin-8, 59:51
 bulimia, fluvoxamine, 59:51
 bulimia, peptides, 59:51
 cholecystokinin-8, anorexia, 59:43
 cholecystokinin-8, bulimia, 59:51
 cortisol, naltrexone, 58:203
 eating disorder, amineptine, 59:43, 59:51
 eating disorder, cholecystokinin-8, 59:43, 59:51
 eating disorder, fluoxetine, 59:43
 eating disorder, fluvoxamine, 59:51
 eating disorder, peptides, 59:43, 59:51
 fluoxetine, anorexia, 59:43
 fluvoxamine, bulimia, 59:51
 naltrexone, autism, 58:191, 58:203
 naltrexone, social behavior, 58:203
 peptides, anorexia, 59:43
 peptides, bulimia, 59:51
 social behavior, autism, 58:203
 social behavior, naltrexone, 58:203

Biperiden

affective disorder, rapid eye movement, sleep, 58:99
 rapid eye movement, sleep, affective disorder, 58:99
 sleep, affective disorder, 58:99

Bipolar affective disorder. See Affective disorder (bipolar subtype)

Blood pressure

abstinence, alcohol dependence, 59:137
 alcohol dependence, abstinence, 59:137
 alcohol dependence, heart rate, 59:137
 anxiety, alcohol dependence, 59:137
 γ -aminobutyric acid, alcohol dependence, 59:137
 heart rate, alcohol dependence, 59:137
 lactate infusion, respiration, 60:77
 liver function, alcohol dependence, 59:137
 lung volume, heart rate, 60:77
 lung volume, lactate infusion, 60:77
 respiration, heart rate, 60:77
 respiration, lactate infusion, 60:77

Borna Disease Virus. See Immunology

Brain tumor

affective psychosis, neurologic signs, 58:177
 meningiomas, neurologic signs, 58:177
 meningiomas, psychiatric disturbance, 58:177
 neurologic signs, peritumoral edema, 58:177
 peritumoral edema, affective psychosis, 58:177
 peritumoral edema, neurologic signs, 58:177
 peritumoral edema, psychiatric disturbance, 58:177
 psychiatric disturbance, meningiomas, 58:177
 psychiatric disturbance, peritumoral edema, 58:177

Brofaramine

affective disorder, response prediction, vs. imipramine, 58:107
 late-life depression, response prediction vs. imipramine, 58:107
 therapeutic outcome, early response as a predictor, 58:107

Bufofenin

personality, serotonin, violence, 58:145
 serotonin, personality, violence, 58:145
 violence, serotonin, personality, 58:145

Bulimia nervosa. See Eating disorder

Calbindin

frontal lobe, γ -aminobutyric acid, local circuit neurons, 59:81
 frontal lobe, schizophrenia, post-mortem study, 59:81
 γ -aminobutyric acid, frontal lobe, 59:81
 γ -aminobutyric acid, local circuit neurons, schizophrenia, 59:81
 schizophrenia, frontal lobe, post-mortem study, 59:81
 schizophrenia, γ -aminobutyric acid, local circuit neurons, 59:81

Calcium

alcohol dependence, serotonin, 57:275
 serotonin, alcohol dependence, 57:275

Calretinin

frontal lobe, γ -aminobutyric acid, local circuit neurons, 59:81
 frontal lobe, schizophrenia, post-mortem study, 59:81
 γ -aminobutyric acid, frontal lobe, local circuit neurons, 59:81
 schizophrenia, frontal lobe, post-mortem study, 59:81
 schizophrenia, γ -aminobutyric acid, local circuit neurons, 59:81

Carbohydrate craving

affective disorder, circannual rhythm, light therapy, 59:171
 circannual rhythm, seasonal affective disorder, 59:171
 circannual rhythm, taste detection, 59:171
 light therapy, seasonal affective disorder, 59:171
 seasonal affective disorder, light therapy, 59:171
 seasonal affective disorder, taste detection, 59:171
 taste detection, seasonal affective disorder, 59:171

Carbon dioxide

agoraphobia, anxiety disorder, panic attacks, 57:267
 anxiety disorder, agoraphobia, panic attacks, 57:267
 panic attacks, agoraphobia, 57:267

Child abuse

adult survivors, Early Trauma Inventory, 59:97
 adult survivors, memory, 59:97
 Early Trauma Inventory, neuropsychology, 59:97
 memory, Early Trauma Inventory, 59:97
 neuropsychology, adult survivors, 59:97

Child psychiatry. See Attention deficit hyperactivity disorder; Autism; Conduct disorder; Obsessive-compulsive disorder

Cholecystokinin-8

amineptine, anorexia, 59:43
 amineptine, bulimia, 59:51
 anorexia, amineptine, 59:43
 anorexia, fluoxetine, 59:43
 anorexia, T-lymphocytes, 59:43
 bulimia, amineptine, 59:51
 bulimia, fluvoxamine, 59:51
 bulimia, T-lymphocytes, 59:51
 eating disorder, amineptine, 59:43, 59:51
 eating disorder, fluoxetine, 59:43
 eating disorder, fluvoxamine, 59:51
 eating disorder, T-lymphocytes, 59:43, 59:51
 fluoxetine, anorexia, 59:43
 fluvoxamine, bulimia, 59:51
 T-lymphocytes, eating disorder, 59:43, 59:51

Cholinesterase, serum

anxiety, fluvoxamine, 58:265
 anxiety, obsessive-compulsive disorder, 58:265
 fluvoxamine, anxiety, 58:265
 fluvoxamine, obsessive-compulsive disorder, 58:265
 obsessive-compulsive disorder, anxiety, 58:265
 obsessive-compulsive disorder, fluvoxamine, 58:265

Circadian rhythm

Abnormal Involuntary Movements Scale, haloperidol, 56:53
 Abnormal Involuntary Movements Scale, schizophrenia, 56:53
 Abnormal Involuntary Movements Scale, tardive dyskinesia, 56:53
 affective disorder, Arden ratio, 57:197
 affective disorder, circannual rhythm, 56:221, 60:199
 affective disorder, electrooculography, 57:197
 affective disorder, light therapy, 56:221
 affective disorder, melatonin, 56:221
 affective disorder, photoperiod, 60:199
 affective disorder, sleep, deprivation, 57:197
 affective disorder, violence, 60:199
 affective disorder, visual adaptation, 57:197
 Alaska, circannual rhythm, 57:251
 Alaska, nurses' medication errors, 57:251
 animal model, hamster, effects of carbamazepine, lithium, valproate, verapamil, 57:215
 blood pressure, body temperature, heart rate, 57:21
 blood pressure, norepinephrine, 57:21
 blood pressure, schizophrenia, 57:21
 body temperature, blood pressure, heart rate, 57:21
 body temperature, schizophrenia, 57:21
 carbamazepine, animal model, hamster, 57:215
 cortisol, schizophrenia, 57:21
 electrooculography, affective disorder, 57:197
 electrooculography, Arden ratio, 57:197
 electrooculography, sleep, sleep deprivation, 57:197
 electrooculography, visual adaptation, 57:197
 haloperidol, Abnormal Involuntary Movements Scale, 56:53
 haloperidol, schizophrenia, 56:53
 haloperidol, tardive dyskinesia, 56:53
 hamster, animal model, effects of carbamazepine, lithium, valproate, verapamil, 57:215
 heart rate, blood pressure, body temperature, 57:21
 heart rate, schizophrenia, 57:21
 light therapy, affective disorder, 56:221
 light therapy, circannual rhythm, 56:221
 light therapy, melatonin, 56:221
 light therapy, seasonal affective disorder, 56:221
 lithium, animal model, hamster, 57:215
 melatonin, affective disorder, 56:221
 melatonin, circannual rhythm, 56:221
 melatonin, light therapy, 56:221
 melatonin, seasonal affective disorder, 56:221
 norepinephrine, blood pressure, 57:21
 norepinephrine, schizophrenia, 57:21
 photoperiod, affective disorder, 60:199
 photoperiod, circannual rhythm, 60:199
 photoperiod, violence, 60:199
 schizophrenia, Abnormal Involuntary Movements Scale, 56:53
 schizophrenia, blood pressure, 57:21
 schizophrenia, body temperature, 57:21
 schizophrenia, cortisol, 57:21
 schizophrenia, haloperidol, 56:53
 schizophrenia, heart rate, 57:21
 schizophrenia, norepinephrine, 57:21
 schizophrenia, photoperiod, 60:199
 schizophrenia, tardive dyskinesia, 56:53
 schizophrenia, thyroid hormones, 57:21
 seasonal affective disorder, light therapy, 56:221
 seasonal affective disorder, melatonin, 56:221
 sleep, affective disorder, 57:197
 sleep deprivation, affective disorder, 57:197
 sleep, electrooculography, 57:197
 tardive dyskinesia, Abnormal Involuntary Movements Scale, 56:53
 tardive dyskinesia, haloperidol, 56:53
 tardive dyskinesia, schizophrenia, 56:53
 thyroid hormones, schizophrenia, 57:21
 valproate, animal model, hamster, 57:215

verapamil, animal model, hamster, 57:215
 violence, photoperiod, 60:199
 visual adaptation, affective disorder, 57:197
 visual adaptation, Arden ratio, 57:197
 visual adaptation, electrooculography, 57:197
 work performance, Alaska, 57:251
 work performance, nurses' medication errors, 57:251

Circannual rhythm

affective disorder, carbohydrate craving, 59:171
 affective disorder, circadian rhythm, 56:221, 60:199
 affective disorder, electrooculographic ratio, 59:151
 affective disorder, ethology, 57:223
 affective disorder, light therapy, 56:11, 56:221, 57:223, 59:171
 affective disorder, melatonin, 56:221
 affective disorder, photoperiod, 60:199
 affective disorder, retina, 59:151
 affective disorder, taste detection, 59:171
 carbohydrate craving, affective disorder, 59:171
 carbohydrate craving, light therapy, 59:171
 carbohydrate craving, seasonal affective disorder, 59:171
 carbohydrate craving, taste detection, 59:171
 electrooculographic ratio, affective disorder, 59:151
 electrooculographic ratio, retina, 59:151
 electrooculographic ratio, seasonal affective disorder, 59:151
 ethology, affective disorder, 57:223
 ethology, light therapy, 57:223
 ethology, seasonal affective disorder, 57:223
 light therapy, carbohydrate craving, 59:171
 light therapy, ethology, 57:223
 light therapy, melatonin, 56:221
 light therapy, seasonal affective disorder, 56:11, 56:221, 57:223, 59:171
 light therapy, Southern Hemisphere, 56:11
 light therapy, taste detection, 59:171
 melatonin, affective disorder, 56:221
 melatonin, light therapy, 56:221
 melatonin, seasonal affective disorder, 56:221
 photoperiod, affective disorder, 60:199
 photoperiod, circadian rhythm, 60:199
 photoperiod, schizophrenia, 60:199
 photoperiod, violence, 60:199
 retina, affective disorder, 59:151
 retina, electrooculographic ratio, 59:151
 retina, seasonal affective disorder, 59:151
 schizophrenia, photoperiod, 60:199
 seasonal affective disorder, carbohydrate craving, 59:171
 seasonal affective disorder, electrooculographic ratio, 59:151
 seasonal affective disorder, ethology, 57:223
 seasonal affective disorder, light therapy, 56:11, 56:221, 57:223, 59:171
 seasonal affective disorder, melatonin, 56:221
 seasonal affective disorder, retina, 59:151
 seasonal affective disorder, Southern Hemisphere, 56:11
 seasonal affective disorder, taste detection, 59:171
 taste detection, affective disorder, 59:171

taste detection, carbohydrate craving, 59:171
 taste detection, light therapy, 59:171
 taste detection, seasonal affective disorder, 59:171
 violence, photoperiod, 60:199
 work performance, Alaska, 57:251
 work performance, nurses' medication errors, 57:251

Clonidine

affective disorder, cortisol, dexamethasone, 60:23
 affective disorder, growth hormone, 60:23
 cortisol, dexamethasone, affective disorder, 60:23
 dexamethasone, cortisol, affective disorder, 60:23
 growth hormone, affective disorder, 60:23

Cognition. See also Attention; Neuropsychology

Allen Cognitive Levels, cross-cultural comparison, African-American, Mexican-American, 56:101
 Mexican-American, 56:101
 Allen Cognitive Levels, schizoaffective disorder, schizophrenia, 56:101
 Alzheimer's Disease, deprenyl effects, 58:181
 Alzheimer's Disease, monoamine oxidase inhibitor, 58:181
 Alzheimer's Disease, physostigmine, 58:181
 backward masking, personality disorder, 60:49
 backward masking, schizophrenia, schizotypal personality, 60:49
 Continuous Performance Test, personality disorder, 60:49
 Continuous Performance Test, schizophrenia, schizotypal personality, 60:49
 cross-cultural, African-American, Mexican-American, 56:101
 cross-cultural, schizoaffective disorder, schizophrenia, 56:101
 dementia, deprenyl, 58:181
 dementia, monoamine oxidase inhibitor, 58:181
 dementia, physostigmine, 58:181
 deprenyl, Alzheimer's Disease, 58:181
 deprenyl, dementia, 58:181
 monoamine oxidase inhibitor, Alzheimer's Disease, 58:181
 monoamine oxidase inhibitor, dementia, 58:181
 memory, schizoaffective disorder, schizophrenia, 57:141
 memory, sex difference, 57:141
 memory, social skill, 57:141
 personality disorder, backward masking, 60:49
 personality disorder, Continuous Performance Test, 60:49
 physostigmine, Alzheimer's Disease, 58:181
 physostigmine, dementia, 58:181
 schizoaffective disorder, Allen Cognitive Levels, 56:101
 schizoaffective disorder, cross-cultural, 56:101
 schizoaffective disorder, memory, 57:141
 schizoaffective disorder, sex difference, 57:141
 schizoaffective disorder, social skill, 57:141
 schizophrenia, Allen Cognitive Levels, 56:101
 schizophrenia, backward masking, 60:49
 schizophrenia, Continuous Performance Test, 60:49
 schizophrenia, cross-cultural, 56:101
 schizophrenia, memory, 57:141

schizophrenia, sex difference, 57:141
 schizophrenia, social skill, 57:141
 schizotypal personality, backward masking, 60:49
 schizotypal personality, Continuous Performance Test, 60:49
 sex, memory, 57:141
 sex, schizoaffective disorder, schizophrenia, 57:141
 sex, social skill, 57:141
 social skill, memory, 57:141
 social skill, schizoaffective disorder, 57:141
 social skill, sex, 57:141

Conduct disorder

aggression, genetics, 59:35
 dinucleotide repeat polymorphism, monoamine oxidase type A gene, 59:35
 genetics, polymerase chain reaction, 59:35
 monoamine oxidase type A gene, 59:35

Cortisol

abstinence, alcohol dependence, 56:81
 affective disorder, clonidine, 60:23
 affective disorder, computed tomography, 59:157
 affective disorder, desipramine, 60:191
 affective disorder, dexamethasone, 60:23
 alcohol dependence, abstinence, 56:81
 atypical depression, desipramine, 60:191
 autism, naltrexone, 58:203
 circadian rhythm, schizophrenia, 57:21
 computed tomography, affective disorder, 59:157
 desipramine, affective disorder, 60:191
 desipramine, atypical depression, 60:191
 dexamethasone, affective disorder, 60:23
 dexamethasone, metyrapone, 58:23
 heroin, substance dependence, 58:153
 impulsivity, personality, 60:177
 meta-chlorophenylpiperazine, pindolol, 58:89
 metyrapone, dexamethasone, 58:23
 naltrexone, autism, 58:203
 naltrexone, β -endorphin, 58:203
 naltrexone, social behavior, 58:203
 pindolol, meta-chlorophenylpiperazine, 58:89
 schizophrenia, circadian rhythm, 57:21

Computed tomography

personality disorder, ventricle-brain ratio, 57:109
 schizophrenia, ventricle-brain ratio, 57:109, 60:125
 schizotypal personality disorder, ventricle-brain ratio, 57:109
 ventricle-brain ratio, personality disorder, 57:109
 ventricle-brain ratio, schizophrenia, 57:109, 60:125
 ventricle-brain ratio, schizotypal personality disorder, 57:109

Cost-benefit analysis

bulimia, cognitive-behavioral therapy, desipramine, 58:13
 cognitive-behavioral therapy, desipramine, bulimia, 58:13
 desipramine, cognitive-behavioral therapy, bulimia, 58:13

Cross-cultural

African-American, Allen Cognitive Levels, 56:101

African-American, schizoaffective disorder, schizophrenia, 56:101
 Allen Cognitive Levels, African-American, Mexican-American, 56:101
 Allen Cognitive Levels, schizoaffective disorder, schizophrenia, 56:101
 Center for Epidemiologic Studies Depression Scale, Japan vs. U.S., 58:237
 cognition, African-American, Mexican-American, 56:101
 cognition, schizoaffective disorder, schizophrenia, 56:101
 depression, epidemiology, Japan vs. U.S., 58:237
 epidemiology, depression, Japan vs. U.S., 58:237
 Mexican-American, Allen Cognitive Levels, 56:101
 Mexican-American, schizoaffective disorder, schizophrenia, 56:101
 schizoaffective disorder, African-American, Mexican-American, 56:101
 schizoaffective disorder, Allen Cognitive Levels, 56:101
 schizophrenia, African-American, Mexican-American, 56:101
 schizophrenia, Allen Cognitive Levels, 56:101
Dementia. See also Alzheimer's Disease
 age, brain volume, 57:119
 age, magnetic resonance imaging, 57:119
 age, sex, 57:119
 age, temporal lobe, 57:119
 agitation, light therapy, 57:7
 agitation, sundowning, 57:7
 anticardiolipin antibody, immunology, 58:83
 anticardiolipin antibody, vascular signs, 58:83
 autoantibody reactivity, immunology, 59:251
 brain volume, age, 57:119
 brain volume, discriminant analysis, 57:119
 brain volume, magnetic resonance imaging, 57:119
 brain volume, sex, 57:119
 brain volume, temporal lobe, 57:119
 cognition, deprenyl, 58:181
 cognition, monoamine oxidase inhibitor, 58:181
 cognition, physostigmine, 58:181
 deprenyl, cognition, 58:181
 distractibility, age, 57:119
 distractibility, brain volume, 57:119
 distractibility, magnetic resonance imaging, 57:119
 distractibility, sex, 57:119
 distractibility, temporal lobe, 57:119
 evoked potentials, genetics, 57:57
 evoked potentials, oddball paradigm, 57:57
 evoked potentials, risk study, 57:57
 genetics, evoked potentials, 57:57
 genetics, risk study, 57:57
 immunology, anticardiolipin antibody, 58:83
 immunology, autoantibody reactivity, 59:251
 immunology, vascular signs, 58:83
 light therapy, agitation, 57:7
 light therapy, sundowning, 57:7
 magnetic resonance imaging, age, 57:119
 magnetic resonance imaging, brain volume, 57:119

magnetic resonance imaging, discriminant analysis, 57:119
 magnetic resonance imaging, sex, 57:119
 magnetic resonance imaging, temporal lobe, 57:119
 monoamine oxidase inhibitor, cognition, 58:181
 pharmacokinetics, serotonin, 59:145
 physostigmine, cognition, 58:181
 serotonin, pharmacokinetics, 59:145
 sex, age, 57:119
 sex, brain volume, 57:119
 sex, magnetic resonance imaging, 57:119
 sex, temporal lobe, 57:119
 sundowning, agitation, 57:7
 sundowning, light therapy, 57:7
 temporal lobe, age, 57:119
 temporal lobe, magnetic resonance imaging, 57:119
 temporal lobe, sex, 57:119
 vascular signs, anticardiolipin antibody, 58:83
 vascular signs, immunology, 58:83

2-Deoxyglucose

amphetamine, rat, 57:65
 local cerebral glucose, amphetamine, 57:65
 local cerebral glucose, rat, 57:65

Deprenyl

Alzheimer's Disease, cognition, 58:181
 cognition, Alzheimer's Disease, dementia, 58:181
 monoamine oxidase inhibitor, dementia, 58:181

Depressed mood

human immunodeficiency virus, intake interview, 59:245
 human immunodeficiency virus, Structured Clinical Interview for DSM-III-R, 59:245
 human immunodeficiency virus, visual analogue scale, 59:245
 intake interview, Structured Clinical Interview for DSM-III-R, 59:245
 Structured Clinical Interview for DSM-III-R, human immunodeficiency virus, 59:245
 visual analogue scale, human immunodeficiency virus, 59:245

Dexamethasone

affective disorder, cortisol, 60:23
 cortisol, affective disorder, 60:23
 cortisol, metyrapone, 58:23
 metyrapone, cortisol, 58:23
 Dinucleotide repeat polymorphism
 aggression, conduct disorder, genetics, 59:35
 aggression, monoamine oxidase type A gene, 59:35
 conduct disorder, genetics, 59:35
 conduct disorder, monoamine oxidase type A gene, 59:35
 genetics, aggression, conduct disorder, 59:35
 genetics, polymerase chain reaction, 59:35
 monoamine oxidase type A gene, aggression, conduct disorder, 59:35

Dopamine

animal model, rat, apomorphine, 58:165

apomorphine, animal model, rat, 58:165
 French population, genetics, linkage analysis, schizophrenia, 59:1
 genetics, linkage analysis, schizophrenia, 59:1
 homovanillic acid, prolactin, 58:23
 linkage analysis, genetics, schizophrenia, 59:1
 prolactin, homovanillic acid, 58:23
 rat, animal model, apomorphine, 58:165
 schizophrenia, French population, genetics, linkage analysis, 59:1

Dopamine- β -hydroxylase

affective disorder, bipolar subtype, 59:165
 affective disorder, lithium, 59:165
 bipolar affective disorder, lithium, 59:165
 lithium, affective disorder, bipolar subtype, 59:165

Eating disorder

aggression, anorexia, bulimia, 56:205
 amineptine, anorexia, 59:43
 amineptine, β -endorphin, 59:43, 59:51
 amineptine, bulimia, 59:51
 amineptine, cholecystokinin-8, 59:43, cholecystokinin-8, 59:51
 anger attacks, anorexia, bulimia, 56:205
 anorexia, aggression, 56:205
 anorexia, amineptine, 59:43
 anorexia, anger attacks, 56:205
 anorexia, β -endorphin, 59:43
 anorexia, cholecystokinin-8, 59:43
 anorexia, cholesterol, 59:255
 anorexia, erythrocyte membrane, 59:255
 anorexia, fluoxetine, 59:43
 anorexia, lipids, 59:255
 anorexia, peptides, 59:43
 anorexia, refeeding, 59:255
 anorexia, T-lymphocytes, 59:43
 β -endorphin, amineptine, 59:43, 59:51
 β -endorphin, anorexia, 59:43
 β -endorphin, bulimia, 59:51
 β -endorphin, cholecystokinin-8, 59:43, 59:51
 β -endorphin, fluoxetine, 59:43
 β -endorphin, fluvoxamine, 59:51
 β -endorphin, T-lymphocytes, 59:43, 59:51
 bulimia, aggression, 56:205
 bulimia, amineptine, 59:51
 bulimia, anger attacks, 56:205
 bulimia, β -endorphin, 59:51
 bulimia, cholecystokinin-8, 59:51
 bulimia, cognitive-behavioral therapy, 58:13
 bulimia, cost-benefit analysis, 58:13
 bulimia, depression, 60:1
 bulimia, desipramine, 58:13
 bulimia, fluvoxamine, 59:51
 bulimia, light therapy, 60:1
 bulimia, T-lymphocytes, 59:51
 bulimia, peptides, 59:51

cholecystokinin-8, amineptine, 59:43, 59:51
 cholecystokinin-8, anorexia, 59:43
 cholecystokinin-8, β -endorphin, 59:43, 59:51
 cholecystokinin-8, bulimia, 59:51
 cholecystokinin-8, fluoxetine, 59:43
 cholecystokinin-8, fluvoxamine, 59:51
 cholecystokinin-8, T-lymphocytes, 59:43, 59:51
 cholesterol, anorexia, 59:255
 cholesterol, erythrocyte membrane, 59:255
 cholesterol, lipids, 59:255
 cholesterol, refeeding, 59:255
 cognitive-behavioral therapy, bulimia, 58:13
 cognitive-behavioral therapy, cost-benefit analysis, 58:13
 cognitive-behavioral therapy, desipramine, 58:13
 cost-benefit analysis, bulimia, 58:13
 cost-benefit analysis, cognitive-behavioral therapy, 58:13
 cost-benefit analysis, desipramine, 58:13
 depression, bulimia, 60:1
 desipramine, bulimia, 58:13
 desipramine, cognitive-behavioral therapy, 58:13
 desipramine, cost-benefit analysis, 58:13
 erythrocyte membrane, anorexia, 59:255
 erythrocyte membrane, cholesterol, 59:255
 erythrocyte membrane, lipids, 59:255
 fluoxetine, amineptine, 59:43
 fluoxetine, anorexia, 59:43
 fluoxetine, β -endorphin, 59:43
 fluoxetine, cholecystokinin-8, 59:43
 fluoxetine, peptides, 59:43
 fluvoxamine, amineptine, 59:51
 fluvoxamine, β -endorphin, 59:51
 fluvoxamine, bulimia, 59:51
 fluvoxamine, cholecystokinin-8, 59:51
 fluvoxamine, peptides, 59:51
 light therapy, bulimia, 60:1
 lipids, anorexia, 59:255
 lipids, cholesterol, 59:255
 lipids, erythrocyte membrane, 59:255
 lipids, refeeding, 59:255
 peptides, anorexia, 59:43
 peptides, bulimia, 59:51
 refeeding, anorexia, 59:255
 T-lymphocytes, β -endorphin, 59:43, 59:51
 T-lymphocytes, bulimia, 59:51
 T-lymphocytes, cholecystokinin-8, 59:43

Electroconvulsive therapy

affective disorder, ondansetron, prolactin, serotonin, 60:33
 ondansetron, affective disorder, prolactin, serotonin, 60:33
 prolactin, ondansetron, serotonin, affective disorder, 60:33
 serotonin, prolactin, ondansetron, affective disorder, 60:33

Electroencephalography. See also Evoked potentials; Polysomnography

alcohol, substance dependence, 58:247
 cocaine, marijuana, 58:247
 marijuana, alcohol, cocaine, 58:247
 substance dependence, 58:247

Electrooculography

affective disorder, Arden ratio, 57:197
 affective disorder, circadian rhythm, 57:197
 affective disorder, circannual rhythm, 59:151
 affective disorder, retina, 59:151
 affective disorder, visual adaptation, 57:197
 Arden ratio, affective disorder, 57:197
 Arden ratio, circadian rhythm, 57:197
 Arden ratio, visual adaptation, 57:197
 attention, schizophrenia, 59:221
 attention, smooth pursuit eye movements, 59:221
 attention, tardive dyskinesia, 59:221
 caudate nucleus, eye movements, 58:53
 caudate nucleus, frontal eye fields, 58:53
 caudate nucleus, positron emission tomography, 58:53
 caudate nucleus, schizophrenia, 58:53
 caudate nucleus, smooth pursuit eye movements, 58:53
 circadian rhythm, affective disorder, 57:197
 circadian rhythm, Arden ratio, 57:197
 circadian rhythm, visual adaptation, 57:197
 circannual rhythm, affective disorder, 59:151
 circannual rhythm, retina, 59:151
 circannual rhythm, seasonal affective disorder, 59:151
 eye movements, caudate nucleus, 58:53
 eye movements, frontal eye fields, 58:53
 eye movements, positron emission tomography, 58:53
 eye movements, schizophrenia, 58:53
 eye movements, smooth pursuit, 58:53
 frontal eye fields, caudate nucleus, 58:53
 frontal eye fields, eye movements, 58:53
 frontal eye fields, positron emission tomography, 58:53
 frontal eye fields, schizophrenia, 58:53
 frontal eye fields, smooth pursuit tracking, 58:53
 positron emission tomography, caudate nucleus, 58:53
 positron emission tomography, frontal eye fields, 58:53
 positron emission tomography, schizophrenia, 58:53
 positron emission tomography, smooth pursuit eye movements, 58:53
 retina, affective disorder, 59:151
 retina, circannual rhythm, 59:151
 retina, seasonal affective disorder, 59:151
 schizophrenia, attention, 59:221
 schizophrenia, caudate nucleus, 58:53
 schizophrenia, eye movements, 58:53
 schizophrenia, frontal eye fields, 58:53
 schizophrenia, positron emission tomography, 58:53
 schizophrenia, smooth pursuit eye tracking, 58:53, 59:221
 schizophrenia, tardive dyskinesia, 59:221
 seasonal affective disorder, circannual rhythm, 59:151
 seasonal affective disorder, retina, 59:151
 smooth pursuit eye tracking, attention, 59:221
 smooth pursuit eye tracking, caudate nucleus, 58:53
 smooth pursuit eye tracking, positron emission tomography, 58:53
 smooth pursuit eye tracking, schizophrenia, 58:53, 59:221
 smooth pursuit eye tracking, tardive dyskinesia, 59:221
 tardive dyskinesia, attention, 59:221

tardive dyskinesia, schizophrenia, 59:221
 tardive dyskinesia, smooth pursuit eye tracking, 59:221
 visual adaptation, affective disorder, 57:197
 visual adaptation, Arden ratio, 57:197
 visual adaptation, circadian rhythm, 57:197

Epidemiology

affective disorder, anxiety disorder, 57:169, 58:1, 59:57
 affective disorder, bipolar subtype, 59:57
 affective disorder, Family History Screen for Epidemiologic Studies, 57:169
 affective disorder, genetics, 57:169
 affective disorder, obsessive-compulsive disorder, 59:57
 affective disorder, panic disorder, 59:57
 affective disorder, sex, 58:1
 affective disorder, substance abuse, 57:169
 affective disorder, suicidality, 59:57
 affective disorder, unipolar subtype, 59:57
 anxiety disorder, affective disorder, 57:169, 58:1, 59:57
 anxiety disorder, Family History Screen for Epidemiologic Studies, 57:169
 anxiety disorder, genetics, 57:169
 anxiety disorder, obsessive-compulsive disorder, 59:57
 anxiety disorder, sex, 58:1
 anxiety disorder, substance abuse, 57:169
 bipolar affective disorder, suicidality, 59:57
 Center for Epidemiologic Studies Depression Scale, cross-cultural, 58:237
 Center for Epidemiologic Studies Depression Scale, Japan vs. U.S., 58:237
 comorbidity, 59:57
 cross-cultural, Center for Epidemiologic Studies Depression Scale, 58:237
 cross-cultural, Japan vs. U.S., 58:237
 depression, cross-cultural, Japan vs. U.S., 58:237
 Family History Screen for Epidemiologic Studies, genetics, 57:169
 genetics, affective disorder, anxiety disorder, substance abuse, 57:169
 obsessive-compulsive disorder, affective disorder, 59:57
 obsessive-compulsive disorder, anxiety disorder, 59:57
 obsessive-compulsive disorder, panic disorder, 59:57
 panic disorder, affective disorder, 59:57
 panic disorder, obsessive-compulsive disorder, 59:57
 schizophrenia, season of birth, 60:205
 schizophrenia, Southern Hemisphere, 60:205
 season of birth, schizophrenia, 60:205
 season of birth, Southern Hemisphere, 60:205
 sex, affective disorder, 58:1
 sex, anxiety disorder, 58:1
 substance abuse, affective disorder, 57:169
 substance abuse, anxiety disorder, 57:169
 substance abuse, Family History Screen for Epidemiologic Studies, 57:169
 substance abuse, genetics, 57:169
 suicidality, bipolar affective disorder, 59:57
 unipolar depression, anxiety disorder, 59:57
 unipolar depression, suicidality, 59:57

Ethology

circannual rhythm, seasonal affective disorder, light therapy, 57:223
 light therapy, seasonal affective disorder, circannual rhythm, 57:223
 seasonal affective disorder, light therapy, circannual rhythm, 57:223

Evoked potentials

Alzheimer's Disease, risk study, 57:57
 attention, P300 component, oddball paradigm, 58:69
 attention, reaction time, schizophrenia, 58:69
 dementia, risk study, 57:57
 gating, mismatch detection, 57:83
 gating, P50 component, 56:271, 57:83
 gating, rapid eye movement sleep, 56:271
 gating, schizophrenia, 56:271
 gating, slow wave sleep, 56:271
 genetics, Alzheimer's Disease, 57:57
 genetics, dementia, 57:57
 genetics, risk study, 57:57
 mismatch detection, gating, P50 component, 57:83
 neuroleptic effects, late component, 56:229
 neuroleptic effects, schizophrenia, 56:229
 reaction time, attention, P300 component, schizophrenia, 58:69
 rapid eye movement sleep, gating, P50 component, schizophrenia, 56:271
 schizophrenia, attention, 58:69
 schizophrenia, gating, 56:271
 schizophrenia, neuroleptic effects on late component, 56:229
 schizophrenia, oddball paradigm, 56:237
 schizophrenia, P300 component, 58:69
 schizophrenia, P50 component, 56:271
 schizophrenia, reaction time, 58:69
 schizophrenia, rapid eye movement sleep, 56:271
 schizophrenia, slow wave sleep, 56:271
 schizophrenia, variability, 56:237
 sleep, gating, P50 component, 56:271
 sleep, rapid eye movement, 56:271
 sleep, schizophrenia, 56:271
 sleep, slow wave, 56:271
 slow wave sleep, gating, P50 component, schizophrenia, 56:271
 variability, oddball paradigm, schizophrenia, 56:237

Expressed emotion

affective disorder, bipolar subtype, 56:299
 affective disorder, family therapy, psychoeducation, 56:299
 bipolar affective disorder, family therapy, psychoeducation, 56:299
 communication deviance, family interactions, 56:121
 communication deviance, prognosis, 56:121
 communication deviance, schizoaffective disorder, schizophrenia, 56:121
 communication deviance, social skills, 56:121
 content analysis, family environment, 57:155
 content analysis, speech, 57:155
 family environment, content analysis, 57:155
 family environment, schizophrenia, 57:155

family environment, speech, 57:155
 family interactions, communication deviance, 56:121
 family interactions, prognosis, 56:121
 family interactions, schizoaffective disorder, schizophrenia, 56:121
 family interactions, social skills, 56:121
 family therapy, affective disorder, bipolar subtype, 56:299
 family therapy, psychoeducation, 56:299
 prognosis, communication deviance, family interactions, 56:121
 prognosis, schizoaffective disorder, schizophrenia, 56:121
 prognosis, social skills, 56:121
 psychoeducation, affective disorder, bipolar subtype, 56:299
 psychoeducation, family therapy, 56:299
 schizoaffective disorder, communication deviance, 56:121
 schizoaffective disorder, family interactions, 56:121
 schizoaffective disorder, prognosis, 56:121
 schizoaffective disorder, social skills, 56:121
 schizophrenia, communication deviance, 56:121
 schizophrenia, family environment, 57:155
 schizophrenia, family interactions, 56:121
 schizophrenia, prognosis, 56:121
 schizophrenia, social skills, 56:121
 social skills, communication deviance, 56:121
 social skills, family interactions, 56:121
 social skills, schizoaffective disorder, schizophrenia, 56:121
 speech, content analysis, family environment, 57:155

Fenfluramine

cortisol, depression, 58:153
 cortisol, heroin abuse, 58:153
 heroin abuse, comorbid depression, 58:153
 heroin abuse, cortisol, 58:153
 heroin abuse, prolactin, 58:153
 prolactin, depression, 58:153
 prolactin, heroin abuse, 58:153

Gamma-aminobutyric acid

alcohol dependence, levels during abstinence and withdrawal, 59:137
 alcohol dependence, liver function, 59:137
 anxiety, liver function, 59:137
 baclofen, growth hormone, 60:41
 calbindin, frontal lobe, local circuit neurons, 59:81
 calbindin, post-mortem study, schizophrenia, 59:81
 calretinin, frontal lobe, local circuit neurons, 59:81
 calretinin, post-mortem study, schizophrenia, 59:81
 frontal lobe, calbindin, calretinin, local circuit neurons, 59:81
 liver function, alcohol dependence, 59:137
 liver function, anxiety, 59:137
 local circuit neurons in the frontal lobe, calbindin, calretinin, 59:81
 local circuit neurons, schizophrenia, post-mortem study, 59:81
 schizophrenia, calbindin, calretinin, 59:81
 schizophrenia, frontal lobe, local circuit neurons, post-mortem study, 59:81

Genetics

affective disorder, bipolar subtype, 59:7
 affective disorder, chromosome 18, 59:7
 affective disorder, Family History Screen for Epidemiologic Studies, 57:169
 affective disorder, linkage analysis, 59:7
 age of onset, anticipation, schizophrenia, 59:25
 aggression, conduct disorder, 59:35
 aggression, dinucleotide repeat polymorphism, 59:35
 aggression, monoamine oxidase type A gene, 59:35
 anxiety disorder, Family History Screen for Epidemiologic Studies, 57:169
 attention deficit hyperactivity disorder, serotonin, 57:13
 bipolar subtype, affective disorder, 59:7
 bipolar subtype, chromosome 18, 59:7
 bipolar subtype, linkage analysis, 59:7
 catatonic subtype, pseudoautosomal inheritance, 59:17
 catatonic subtype, schizophrenia, 59:17
 catatonic subtype, sex concordance, 59:17
 chromosome 18, bipolar affective disorder, 59:7
 chromosome 18, linkage analysis, 59:7
 conduct disorder, dinucleotide repeat polymorphism, 59:35
 conduct disorder, monoamine oxidase type A gene, 59:35
 dinucleotide repeat polymorphism, aggression, 59:35
 dinucleotide repeat polymorphism, conduct disorder, 59:35
 dinucleotide repeat polymorphism, monoamine oxidase type A gene, 59:35
 dinucleotide repeat polymorphism, personality, 59:35
 dinucleotide repeat polymorphism, polymerase chain reaction, 59:35
 dopamine transporter gene, French population, 59:1
 dopamine transporter gene, linkage analysis, 59:1
 dopamine transporter gene, schizophrenia, 59:1
 linkage analysis, affective disorder, bipolar subtype, 59:7
 linkage analysis, chromosome 18, 59:7
 linkage analysis, dopamine transporter gene, French population, 59:1
 linkage analysis, schizophrenia, 59:1
 monoamine oxidase type A gene, aggression, 59:35
 monoamine oxidase type A gene, conduct disorder, 59:35
 monoamine oxidase type A gene, dinucleotide repeat polymorphism, 59:35
 monoamine oxidase type A gene, personality, 59:35
 oppositional-defiant disorder, serotonin, 57:13
 personality, dinucleotide repeat polymorphism, 59:35
 personality, monoamine oxidase type A gene, 59:35
 polymerase chain reaction, dinucleotide repeat polymorphism, 59:35
 pseudoautosomal inheritance, catatonic subtype, 59:17
 pseudoautosomal inheritance, schizophrenia, 59:17
 pseudoautosomal inheritance, sex concordance, 59:17
 schizophrenia, age of onset, 59:25
 schizophrenia, anticipation, 59:25
 schizophrenia, catatonic subtype, 59:17
 schizophrenia, dopamine transporter gene, 59:1
 schizophrenia, French population, 59:1
 schizophrenia, linkage analysis, 59:1
 schizophrenia, pseudoautosomal inheritance, 59:17

schizophrenia, sex concordance, 59:17
 serotonin, attention deficit hyperactivity disorder, 57:13
 serotonin, conduct disorder, 57:13
 serotonin, oppositional-defiant disorder, 57:13
 sex concordance, catatonic subtype, 59:17
 sex concordance, pseudoautosomal inheritance, 59:17
 sex concordance, schizophrenia, 59:17
 substance abuse, Family History Screen for Epidemiologic Studies, 57:169
 substance abuse, twin study, 56:213
 twin study, substance abuse, 56:213

Geriatric psychiatry. *See Affective disorder; Alzheimer's Disease; Dementia; Schizophrenia*

Growth hormone

affective disorder, clonidine, 60:23
 baclofen, γ -aminobutyric acid, 60:41
 clonidine, affective disorder, 60:23
 γ -aminobutyric acid, baclofen, 60:41

Heart rate

affective disorder, amitriptyline, 56:279
 affective disorder, delirium, 56:279
 amitriptyline, affective disorder, 56:279
 amitriptyline, delirium, 56:279
 anxiety disorder, isoproterenol, 56:289
 anxiety disorder, sympathovagal ratio, 56:289
 circadian rhythm, schizophrenia, 57:21
 delirium, affective disorder, 56:279
 delirium, amitriptyline, 56:279
 isoproterenol, anxiety disorder, 56:289
 isoproterenol, panic disorder, 56:289
 isoproterenol, sympathovagal ratio, 56:289
 lactate infusion, cross-spectral analysis, 60:77
 panic disorder, isoproterenol, 56:289
 panic disorder, sympathovagal ratio, 56:289
 schizoaffective disorder, disorganized symptoms, 57:241
 schizoaffective disorder, negative symptoms, 57:241
 schizoaffective disorder, positive symptoms, 57:241
 schizophrenia, circadian rhythm, 57:21
 schizophrenia, disorganized symptoms, 57:241
 schizophrenia, negative symptoms, 57:241
 schizophrenia, norepinephrine, 57:21
 schizophrenia, positive symptoms, 57:241
 spectral analysis, 56:289, 60:77
 spectral analysis, sympathovagal ratio, 56:289
 sympathovagal ratio, anxiety disorder, 56:289
 sympathovagal ratio, isoproterenol, 56:289
 sympathovagal ratio, panic disorder, 56:289

Homovanillic acid

corticosteroid-dopaminergic interaction, 58:23
 dexamethasone vs. metyrapone administration, 58:23

Human immunodeficiency virus

anxiety, visual analogue scale, 59:245

depression, Structured Clinical Interview for DSM-III-R at intake, 59:245
 depression, visual analogue scale, 59:245
 Structured Clinical Interview for DSM-III-R at intake, anxiety, depression, 59:245
 visual analogue scale, anxiety, depression, 59:245
 5-Hydroxyindoleacetic acid
 anxiety disorder, serotonin, 57:1
 anxiety disorder, urinary measures, 57:1
 meta-analysis, schizophrenia, 59:239
 meta-analysis, serotonin, 59:239
 schizophrenia, meta-analysis, 59:239
 schizophrenia, serotonin, 59:161, 59:239
 serotonin, anxiety disorder, 57:1
 serotonin, meta-analysis, 59:239
 serotonin, schizophrenia, 59:161, 59:239
 serotonin, violence, 59:161
 statistics, meta-analysis, 59:239
 violence, serotonin, 59:161
 Hypothalamic-pituitary-gonadal axis
 alcohol dependence, abstinence, 56:81
 gonadotropin, schizophrenia, 57:231
 gonadotropin-releasing hormone, schizophrenia, 57:231
 luteinizing hormone, schizophrenia, 57:231
 schizophrenia, gonadotropin, luteinizing hormone, testosterone, 57:231
 testosterone, schizophrenia, 57:231

Imipramine

affective disorder, combined treatment with paroxetine, 59:189
 affective disorder, response prediction, 58:107
 affective disorder, treatment outcome vs. monoamine oxidase inhibitor brofaromine, 58:107
 paroxetine effects on metabolism, 59:189
 pharmacokinetics, effect of combined treatment with serotonin reuptake inhibitor, 59:189
 serotonin reuptake inhibitor, effects on tricyclic metabolism, 59:189

Immunology

Alzheimer's Disease, autoantibody reactivity, 59:251
 anticardiolipin antibody, dementia, 58:83
 anticardiolipin antibody, vascular signs, 58:83
 autoantibody reactivity, Alzheimer's Disease, 59:251
 autoantibody reactivity, dementia, 59:251
 Borna Disease virus, magnetic resonance imaging, schizophrenia, 56:33
 dementia, anticardiolipin antibody, 58:83
 dementia, autoantibody reactivity, 59:251
 dementia, vascular signs, 58:83
 magnetic resonance imaging, Borna Disease virus, schizophrenia, 56:33
 putamen, Borna Disease virus, 56:33
 schizophrenia, Borna Disease virus, 56:33
 vascular signs, anticardiolipin antibody, 58:83
 vascular signs, dementia, 58:83

Impulsivity

calcium, cortisol, paroxetine, serotonin, 60:177
 cortisol, calcium, paroxetine, cortisol, serotonin, 60:177
 paroxetine, calcium, cortisol, 60:177
 serotonin, calcium, cortisol, 60:177
Inventory of Complicated Grief
 bereavement, factor analysis, 59:65
 depression, factor analysis, 59:65

Intelligence

genetics, schizophrenia, 56:135
 matching fallacy, schizophrenia, 56:135

Isoproterenol

anxiety disorder, heart rate, sympathovagal ratio, 56:289
 heart rate, anxiety-panic disorder, 56:289
 heart rate, spectral analysis, 56:289
 panic disorder, heart rate, sympathovagal ratio, 56:289
 spectral analysis, heart rate, 56:289
 sympathovagal ratio, anxiety-panic disorder, 56:289

Ketone reductase

haloperidol, reduced haloperidol, schizophrenia, 57:101
 schizophrenia, haloperidol, reduced haloperidol, 57:101

Laterality

affective disorder, anhedonia, 56:163
 affective disorder, bipolar subtype, 56:163, 57:279
 affective disorder, motor activity, 57:279
 affective disorder, skin conductance, 56:163
 ambidexterity, schizophrenia, 59:119
 anhedonia, bipolar affective disorder, 56:163
 anhedonia, schizoaffective disorder, schizophrenia, 56:163
 anhedonia, skin conductance, 56:163
 bipolar affective disorder, anhedonia, 56:163
 memory, personality disorder, 56:71
 memory, schizotypal personality, 56:71
 motor activity, bipolar affective disorder, 57:279
 motor activity, schizophrenia, 57:279
 neuropsychology, memory, 56:71
 neuropsychology, personality disorder, 56:71
 neuropsychology, schizotypal personality, 56:71
 personality disorder, memory, 56:71
 personality disorder, neuropsychology, 56:71
 schizoaffective disorder, anhedonia, 56:163
 schizoaffective disorder, skin conductance, 56:163
 schizophrenia, ambidexterity, 59:119
 schizophrenia, anhedonia, 56:163
 schizophrenia, motor activity, 57:279
 schizophrenia, skin conductance, 56:163
 schizotypal personality, memory, 56:71
 skin conductance, affective disorder, anhedonia, 56:163
 skin conductance, schizoaffective disorder, schizophrenia, 56:163

Light therapy

agitation, dementia, sundowning, 57:7

bulimia, depression, 60:1

carbohydrate craving, circannual rhythm, 59:171
carbohydrate craving, seasonal affective disorder, 59:171
carbohydrate craving, taste detection, 59:171
circadian rhythm, melatonin, 56:221
circadian rhythm, seasonal affective disorder, 56:221
circannual rhythm, carbohydrate craving, 59:171
circannual rhythm, ethology, 57:223
circannual rhythm, melatonin, 56:221
circannual rhythm, seasonal affective disorder, 56:11, 56:221, 57:223, 59:171
circannual rhythm, Southern Hemisphere, 56:11
circannual rhythm, taste detection, 59:171
dementia, agitation, sundowning, 57:7
eating disorder, bulimia, depression, 60:1
ethology, seasonal affective disorder, 57:223
melatonin, circadian rhythm, circannual rhythm, 56:221
melatonin, seasonal affective disorder, 56:221
seasonal affective disorder, carbohydrate craving, 59:171
seasonal affective disorder, circadian rhythm, 56:221
seasonal affective disorder, circannual rhythm, 56:11, 56:221, 57:223, 59:171
seasonal affective disorder, ethology, 57:223
seasonal affective disorder, melatonin, 56:221
seasonal affective disorder, Southern Hemisphere, 56:11
seasonal affective disorder, taste detection, 59:171
sundowning, agitation, dementia, 57:7
taste detection, carbohydrate craving, circannual rhythm, 59:171
taste detection, seasonal affective disorder, 59:171

Magnetic resonance imaging

affective disorder, age, 60:117
 affective disorder, white matter hyperintensity, 60:117
 age, affective disorder, 60:117
 age, Alzheimer's Disease, 57:119
 age, brain volume, 57:119
 age, dementia, 57:119
 age, schizophrenia, 60:117
 age, temporal lobe, 57:119
 age, white matter hyperintensity, 60:117
 Alzheimer's Disease, brain volume, temporal lobe, 57:119
 Borna disease virus, putamen, 56:33
 brain volume, age, 57:119
 brain volume, Alzheimer's Disease, 57:119
 brain volume, dementia, 57:119
 brain volume, discriminant analysis, 57:119
 brain volume, sex, 57:119
 cavum septi pellucidi, posttraumatic stress disorder, 58:259
 dementia, age, 57:119
 dementia, brain volume, temporal lobe, 57:119
 discriminant analysis, brain volume, 57:119
 discriminant analysis, temporal lobe, 57:119
 elderly patients, affective disorder, schizophrenia, 60:117
 immunology, Borna disease virus, 56:33
 immunology, schizophrenia, 56:33
 late-life depression, white matter hyperintensity, 60:117

posttraumatic stress disorder, cavum septi pellucidi, 58:259
 putamen, Borna disease virus, 56:33
 putamen, schizophrenia, 56:33
 schizophrenia, age, 60:117
 schizophrenia, immunology, 56:33
 schizophrenia, putamen, 56:33
 schizophrenia, white matter hyperintensity, 60:117
 sex, Alzheimer's Disease, 57:119
 sex, brain volume, 57:119
 sex, dementia, 57:119
 temporal lobe, age, 57:119
 temporal lobe, Alzheimer's Disease, 57:119
 temporal lobe, dementia, 57:119
 temporal lobe, sex, 57:119
 white matter hyperintensity, affective disorder, schizophrenia, 60:117
 white matter hyperintensity, age, 60:117

Magnetic resonance spectroscopy

frontal cortex, phosphomonoesters, frontal cortex, schizophrenia, 57:91
 phosphomonoesters, frontal cortex, schizophrenia, 57:91
 schizophrenia, frontal cortex, phosphomonoesters, 57:91

Mania. See Affective disorder (bipolar subtype)

Melatonin

circadian rhythm, light therapy, seasonal affective disorder, 56:221
 circannual rhythm, light therapy, seasonal affective disorder, 56:221
 light therapy, circadian and circannual rhythms, 56:221
 pharmacokinetics, serotonin, platelets, 57:193
 seasonal affective disorder, circadian and circannual rhythms, 56:221
 seasonal affective disorder, light therapy, 56:221
 serotonin in platelets, pharmacokinetics, 57:193

Memory

adult survivors of child abuse, 59:97
 child abuse, Early Trauma Inventory, 59:97
 Early Trauma Inventory, adult survivors of child abuse, 59:97
 schizoaffective disorder, schizophrenia, 57:141
 schizophrenia, paired associate recognition, 60:135
 schizophrenia, schizoaffective disorder, 57:141

Meningiomas

neurologic signs, peritumoral edema, 58:177
 psychiatric morbidity, peritumoral edema, 58:177

Meta-chlorophenylpiperazine

borderline personality, serotonin, 58:161
 obsessive-compulsive disorder, serotonin, 58:161
 panic disorder, serotonin, 58:161
 personality disorder, serotonin, 58:161
 serotonin, borderline personality, obsessive-compulsive, panic, and personality disorders, social phobia, 58:161
 social phobia, serotonin, 58:161

Metyrapone

comparison with dexamethasone administration, 58:23
 corticosteroid-dopaminergic interaction, 58:23
 homovanillic acid, cortisol, prolactin, 58:23

Monoamine oxidase

affective disorder, bipolar subtype, 59:165
 affective disorder, lithium treatment, 59:165
 aggression, dinucleotide repeat polymorphism, 59:35
 aggression, genetics, 59:35
 bipolar subtype, affective disorder, lithium treatment, 59:165
 conduct disorder, dinucleotide repeat polymorphism, 59:35
 dinucleotide repeat polymorphism, aggression, 59:35
 dinucleotide repeat polymorphism, conduct disorder, 59:35
 dinucleotide repeat polymorphism, genetics, 59:35
 dinucleotide repeat polymorphism, personality, 59:35
 dinucleotide repeat polymorphism, polymerase chain reaction, 59:35
 genetics, aggression, genetics, conduct disorder, personality type, 59:35
 genetics, polymerase chain reaction, 59:35
 lithium, affective disorder, bipolar subtype, 59:165
 personality type, aggression, 59:35
 platelets, affective disorder, bipolar subtype, 59:165
 polymerase chain reaction, dinucleotide repeat polymorphism, genetics, 59:35
 schizophrenia, deficit syndrome, negative symptoms, 56:25

Monoamine oxidase inhibitor

Alzheimer's Disease, cognition, 58:181
 cognition, Alzheimer's Disease, dementia, 58:181
 deprenyl, Alzheimer's Disease, dementia, 58:181
 physostigmine, Alzheimer's Disease, dementia, 58:181

Motor activity

affective disorder, bipolar subtype, laterality, 57:279
 bipolar subtype, affective disorder, laterality, 57:279
 laterality, affective disorder, bipolar subtype, 57:279
 laterality, schizophrenia, 57:279
 schizophrenia, laterality, 57:279

BICNIC-acetyl- β -glucosaminidase

anxiety disorder, Profile of Mood States, 60:185
 panic disorder, Profile of Mood States, 60:185

Naltrexone

autism, β -endorphin, 58:191, 58:203
 autism, cortisol, social behavior, 58:203
 autism, treatment efficacy, 58:191, 58:203
 β -endorphin, autism, 58:191, 58:203
 β -endorphin, cortisol, social behavior, 58:203
 cortisol, autism, β -endorphin, social behavior, 58:203
 social behavior, autism, β -endorphin, cortisol, 58:203
 treatment efficacy in autism, 58:191, 58:203

Neuroleptic effects

attention, Continuous Performance Test, schizophrenia, 57:131

Neurological symptoms

extrapyramidal signs, schizophrenia, 56:183
 motor coordination, schizophrenia, 56:183
 schizophrenia, Cambridge Neurological Inventory, 56:183

Neuropsychology

adult survivors of child abuse, memory, 59:97
 attention, attention deficit hyperactivity disorder, 56:59
 attention deficit hyperactivity disorder, Stroop test, 56:59
 attention, schizophrenia, 56:111, 59:213
 attention, social cue perception, 56:111
 attention, social skill, 59:213
 attention, Stroop test, 56:59
 Brown-Peterson paradigm, frontal lobe, schizophrenia, 56:155
 child abuse survivors, memory performance, 59:97
 cocaine abuse, crack, 60:167
 cognition, cocaine abuse, crack, 60:167
 cognition, frontal lobe, 56:155, 60:167
 cognition, personality disorder, 59:127
 cognition, schizoaffective disorder, 56:45
 cognition, schizophrenia, 56:45, 56:155, 59:213
 cognition, schizotypal personality, 59:127
 cognition, sex effects, social skill, 59:213
 cognition, work performance, 56:45
 crack, cocaine, cognition, 60:167
 disorganization symptoms, schizophrenia, 58:227
 frontal lobe, Brown-Peterson paradigm, schizophrenia, 56:155
 frontal lobe, obsessive-compulsive disorder, 58:37
 frontal lobe, Wisconsin Card Sorting
 Test, 58:37
 genetics, IQ, matching fallacy, schizophrenia, 56:135
 IQ, genetics, schizophrenia, 56:135
 laterality, memory, 56:71
 laterality, personality disorder, 56:71
 laterality, schizotypal personality, 56:71
 matching fallacy, IQ, schizophrenia, 56:135
 memory, adult survivors of child abuse, 59:97
 memory, laterality, 56:71
 memory, paired associate recognition, 60:135
 memory, personality disorder, 56:71
 memory, schizophrenia, 56:155, 60:135
 memory, schizotypal personality, 56:71
 negative symptoms, schizoaffective disorder, 58:45
 negative symptoms, schizophrenia, 58:45, 58:227
 negative symptoms, Wisconsin Card Sorting Test, 58:45
 obsessive-compulsive disorder, frontal lobe, 58:37
 obsessive-compulsive disorder, Wisconsin Card Sorting
 Test, 58:37
 paired associate recognition, schizophrenia, 60:135
 personality disorder, cognition, 59:127
 personality disorder, laterality, 56:71
 personality disorder, memory, 56:71
 positive symptoms, schizoaffective disorder, 58:45
 positive symptoms, schizophrenia, 58:45, 58:227
 positive symptoms, Wisconsin Card Sorting Test, 58:45
 schizoaffective disorder, cognition, 56:45
 schizoaffective disorder, positive and negative symptoms, 58:45
 schizoaffective disorder, Wisconsin Card Sorting Test, 56:45
 schizoaffective disorder, work performance, 56:45

schizophrenia, attention, 56:111, 59:213

schizophrenia, Brown-Peterson paradigm, 56:155
schizophrenia, cognition, 56:45, 56:155, 59:213
schizophrenia, disorganization symptoms, 58:227
schizophrenia, frontal lobe, 56:155

schizophrenia, genetics, IQ, matching fallacy, 56:135

schizophrenia, memory, 56:155, 60:135
schizophrenia, paired associate recognition, 60:135

schizophrenia, positive and negative symptoms, 58:45, 58:227

schizophrenia, sex effects, 59:213

schizophrenia, social cue perception, 56:111

schizophrenia, social skill, 59:213

schizophrenia, Wisconsin Card Sorting Test, 58:45, 60:135

schizophrenia, work performance, 56:45

schizotypal personality, cognition, 59:127

schizotypal personality, laterality, 56:71

schizotypal personality, memory, 56:71

sex effects, attention, cognition, social skill, 59:213

social cue perception, schizophrenia, 56:111

social skill, attention, cognition, sex effects, schizophrenia, 59:213

Stroop test, attention deficit hyperactivity disorder, 56:59

substance dependence, crack cocaine, cognition, 60:167

Wisconsin Card Sorting Test, cognition, 56:45

Wisconsin Card Sorting Test, frontal lobe, 58:37

Wisconsin Card Sorting Test, memory, 60:135

Wisconsin Card Sorting Test, negative symptoms, 58:45

Wisconsin Card Sorting Test, obsessive-compulsive disorder, 58:37

Wisconsin Card Sorting Test, positive symptoms, 58:45

Wisconsin Card Sorting Test, schizoaffective disorder, 56:45

Wisconsin Card Sorting Test, schizophrenia, 56:45, 58:45, 60:135

Wisconsin Card Sorting Test, work performance, 56:45

work performance, cognition, schizoaffective disorder, schizophrenia, 56:45

work performance, Wisconsin Card Sorting Test, 56:45

Norepinephrine

anxiety disorder, vanillylmandelic acid, 57:1

blood pressure, body temperature, heart rate, 57:21

circadian rhythm, schizophrenia, 57:21

schizophrenia, circadian rhythm, 57:21

vanillylmandelic acid, anxiety disorder, 57:1

Obsessive-compulsive disorder

adolescents, children, 60:67

affective disorder, comorbidity, 59:57

anxiety, cholinesterase, 58:265

checking rituals, obsessive stimulation, positron emission tomography, 60:101

children, adolescents, 60:67

cholinesterase, anxiety, 58:265

epidemiology, comorbid disorders, 59:57

fluvoxamine, cholinesterase, 58:265

frontal lobe, Wisconsin Card Sorting Test, 58:37

heart rate, adolescents, children, 60:67

meta-chlorophenylpiperazine, serotonin, 58:161

neuropsychology, frontal lobe, 58:37
 obsessive stimulation, checking rituals, positron emission tomography, 60:101
 paroxetine binding, platelet, 58:117
 positron emission tomography, checking rituals, obsessive stimulation, 60:101
 serotonin, meta-chlorophenylpiperazine, 58:161
 serotonin, paroxetine binding, platelet, 58:117
 skin conductance, adolescents, children, 60:67
 tic disorder, adolescents, children, 60:67
 Wisconsin Card Sorting Test, frontal lobe, 58:37

Ondansetron

affective disorder, electroconvulsive therapy, prolactin, serotonin, 60:33
 electroconvulsive therapy, affective disorder, prolactin, serotonin, 60:33
 prolactin, affective disorder, electroconvulsive therapy, 60:33
 serotonin, affective disorder, electroconvulsive therapy, 60:33

Opiates. See Beta-endorphin; Naltrexone; Peptides

Pain

bipolar affective disorder, signal detection, stimulus intensity, 56:173
 signal detection, stimulus intensity, bipolar affective disorder, 56:173

Panic disorder

Acute Panic Inventory, panic attacks, 58:127
 agoraphobia, behavior therapy, 56:1
 agoraphobia, carbon dioxide inhalation, 57:267
 animal model, anxiety disorder, 57:181
 behavior therapy, agoraphobia, 56:1
 blood pressure, lactate, 58:127
 blood pressure, panic attacks, 58:127
 carbon dioxide inhalation, agoraphobia, panic attacks, 57:267
 diazepam, panic attacks, 58:127
 heart rate, isoproterenol, 56:289
 heart rate, spectral analysis, 56:289
 isoproterenol, heart rate, 56:289
 isoproterenol, sympathovagal ratio, 56:289
 lactate infusion, Acute Panic Inventory, 58:127
 lactate infusion, blood pressure, 58:127
 lactate infusion, diazepam, 58:127
 lactate infusion, panic attacks, 58:127
 meta-chlorophenylpiperazine, serotonin, 58:161
 N-acetyl- β -glusoaminidase, anxiety, Profile of Mood States, 60:185
 neuropeptide Y, norepinephrine, stress, 59:183
 norepinephrine, neuropeptide Y, stress, 59:183
 panic attacks, Acute Panic Inventory, 58:127
 panic attacks, agoraphobia, 57:267
 panic attacks, blood pressure, 58:127
 panic attacks, carbon dioxide inhalation, 57:267
 panic attacks, diazepam, 58:127
 panic attacks, lactate infusion, 58:127
 peptides, norepinephrine, 59:183

peptides, stress, 59:183
 Profile of Mood States, anxiety, N-acetyl- β -glusoaminidase, 60:185
 rat, animal model of anxiety-panic, alprazolam, clonazepam, yohimbine, 57:181
 rat, dorsal periaqueductal gray matter, intracerebral stimulation, 57:181
 serotonin, meta-chlorophenylpiperazine, 58:161
 spectral analysis, heart rate, 56:289
 stress, neuropeptide Y, stress, norepinephrine, 59:183
 sympathovagal ratio, heart rate, isoproterenol, 56:289
 yohimbine, animal model of panic-anxiety, 57:181

Paroxetine

affective disorder, imipramine, 59:189
 affective disorder, serotonin, 58:117, 59:189
 calcium, cortisol, serotonin, impulsivity, 60:177
 cortisol, calcium, serotonin, impulsivity, 60:177
 imipramine pharmacokinetics, affective disorder, 59:189
 impulsivity, calcium, cortisol, serotonin, 60:177
 obsessive-compulsive disorder, serotonin, 58:117
 personality characteristics, calcium, cortisol, serotonin, 60:177
 pharmacokinetics, imipramine, 59:189
 serotonin, affective disorder, 58:117, 59:189
 serotonin, calcium, cortisol, impulsivity, 60:177
 serotonin, obsessive-compulsive disorder, 58:117
 serotonin, personality characteristics, 60:177
 serotonin, platelet measures, 58:117

Peptides

affective disorder, mania, 58:217
 affective disorder, prolyl endopeptidase, 58:217
 anorexia, β -endorphin, T-lymphocytes, 59:43
 anorexia, cholecystokinin-8, T-lymphocytes, 59:43
 anxiety disorder, neuropeptide Y, 59:183
 β -endorphin, anorexia, 59:43
 β -endorphin, bulimia, 59:51
 β -endorphin, cholecystokinin-8, 59:51
 β -endorphin, T-lymphocytes, 59:51
 bulimia, β -endorphin, 59:51
 bulimia, cholecystokinin-8, 59:51
 cholecystokinin-8, anorexia, 59:43
 cholecystokinin-8, bulimia, 59:51
 eating disorder, β -endorphin, 59:43, 59:51
 eating disorder, cholecystokinin-8, 59:43, 59:51
 T-lymphocytes, β -endorphin and cholecystokinin-8, 59:43, 59:51
 mania, prolyl endopeptidase, 58:217
 neuropeptide Y, panic-anxiety, 59:183
 neuropeptide Y, social phobia, 59:183
 neuropeptide Y, stress, 59:183
 panic disorder, neuropeptide Y, 59:183
 panic disorder, stress, 59:183
 prolyl endopeptidase, affective disorder, mania, 58:217
 prolyl endopeptidase, schizophrenia, 58:217
 schizophrenia, prolyl endopeptidase, 58:217
 social phobia, neuropeptide Y, 59:183
 social phobia, stress, 59:183

stress, anxiety disorder, 59:183
 stress, neuropeptide Y, 59:183
 stress, panic disorder, 59:183
 stress, social phobia, 59:183
 T-lymphocytes, β -endorphin and cholecystokinin-8, eating disorder, 59:43, 59:51

Personality disorder. See also Schizotypal personality

attention, backward masking, 60:49
 attention, Continuous Performance Test, 60:49
 backward masking, attention, cognition, 60:49
 borderline personality, meta-chlorophenylpiperazine, 58:161
 borderline personality, serotonin, 58:161
 bufotenin, serotonin, 58:145
 bufotenin, violence, 58:145
 cognition, neuropsychology, 59:127
 computed tomography, ventricle-brain ratio, 57:109
 Continuous Performance Test, attention, 60:49
 harm avoidance, Tridimensional Personality Questionnaire, 57:209
 laterality, memory, neuropsychology, 56:71
 memory, laterality, 56:71
 meta-chlorophenylpiperazine, borderline personality, 58:161
 meta-chlorophenylpiperazine, serotonin, 58:161
 neuropsychology, cognition, 59:127
 neuropsychology, laterality, memory, 56:71
 serotonin, borderline personality, 58:161
 serotonin, bufotenin, 58:145
 serotonin, impulsivity, 60:177
 serotonin, meta-chlorophenylpiperazine, 58:161
 serotonin, violence, 58:145
 Tridimensional Personality Questionnaire, harm avoidance, 57:209
 ventricle-brain ratio, computed tomography, 57:109
 violence, bufotenin, serotonin, 58:145

Phospholipase A2

animal model, rat, 58:165
 apomorphine, dopamine, 58:165
 dopamine, apomorphine, 58:165

Phosphomonoesters

frontal cortex, magnetic resonance spectroscopy, schizophrenia, 57:91
 magnetic resonance spectroscopy, frontal cortex, schizophrenia, polysomnography, 57:91
 schizophrenia, frontal cortex, magnetic resonance spectroscopy, polysomnography, 57:91

Phototherapy. See Light therapy

Physostigmine

Alzheimer's Disease, cognition, deprenyl, 58:181
 cognition, Alzheimer's Disease, deprenyl, 58:181
 cognition, dementia, deprenyl, 58:181
 dementia, cognition, deprenyl, 58:181
 deprenyl, Alzheimer's Disease, dementia, cognition, 58:181

Pindolol

cortisol, meta-chlorophenylpiperazine, 58:89
 meta-chlorophenylpiperazine, cortisol, prolactin, serotonin, 58:89
 prolactin, meta-chlorophenylpiperazine, 58:89
 serotonin, meta-chlorophenylpiperazine, 58:89

Polysomnography

affective disorder, period amplitude vs. power spectral analysis, 56:245
 Lyapunov exponent, nonlinear analysis, 56:257
 Lyapunov exponent, rapid eye movement sleep, 56:257
 Lyapunov exponent, schizophrenia, 56:257
 nonlinear analysis, Lyapunov exponent, rapid eye movement, schizophrenia, 56:257
 period amplitude vs. power spectral analysis, affective disorder, 56:245
 rapid eye movement, Lyapunov exponent, nonlinear analysis, schizophrenia, 56:257
 rapid eye movement, slow wave sleep, 59:203
 schizophrenia, Lyapunov exponent, nonlinear analysis, 56:257
 schizophrenia, rapid eye movement, 56:257, 59:203
 schizophrenia, slow wave sleep, 57:91, 59:203, 60:125
 slow wave sleep, computed tomography, ventricle-brain ratio, 60:125
 slow wave sleep, magnetic resonance spectroscopy, 57:91
 slow wave sleep, schizophrenia, 57:91, 59:203, 60:125

Positron emission tomography

caudate nucleus, electrooculography, frontal eye fields, schizophrenia, 58:53
 checking rituals, obsessive stimulation, obsessive-compulsive disorder, 60:101
 electrooculography, caudate nucleus, frontal eye fields, schizophrenia, 58:53
 extrapyramidal symptoms, haloperidol, 60:91
 eye movements, frontal eye fields, smooth pursuit tracking, schizophrenia, 58:53
 frontal eye fields, caudate nucleus, electrooculography, schizophrenia, 58:53
 haloperidol, extrapyramidal symptoms, 60:91
 obsessive stimulation, checking rituals, obsessive-compulsive disorder, 60:101
 obsessive-compulsive disorder, checking rituals, obsessive stimulation, 60:101
 olfaction, olfactory projections, orbitofrontal cortex, schizophrenia, 60:113
 olfactory projections, orbitofrontal cortex, schizophrenia, 60:113
 orbitofrontal cortex, olfaction, olfactory projections, schizophrenia, 60:113
 schizophrenia, caudate nucleus, eye movements, frontal eye fields, 58:53
 schizophrenia, olfactory projections, orbitofrontal cortex, 60:113

Posttraumatic stress disorder

cavum septi pellucidi, magnetic resonance imaging, 58:259
 magnetic resonance imaging, cavum septi pellucidi, 58:259

Prolactin

abstinence, alcohol dependence, 56:81
 affective disorder, ondansetron, 60:33
 alcohol dependence, abstinence, 56:81
 dopamine, homovanillic acid, 58:23
 dopamine, metyrapone, 58:23
 fenfluramine, substance dependence, 58:153
 heroin abuse, fenfluramine, 58:153
 homovanillic acid, dopamine, 58:23
 ondansetron, affective disorder, 60:33
 pindolol, meta-chlorophenylpiperazine, 58:89
 substance dependence, comorbid depression, 58:153

Prolyl endopeptidase

affective disorder, mania, schizophrenia, 58:217

Rat. See Animal models

BICSC-adenosylmethionine
 affective disorder, antidepressant effect, 56:295
 antidepressant effect, affective disorder, 56:295

Schizoaffective disorder. See Schizophrenia**Schizophrenia. See also Schizotypal personality**

Abnormal Involuntary Movements Scale, circadian rhythm, 56:53
 Abnormal Involuntary Movements Scale, haloperidol, 56:53
 Abnormal Involuntary Movements Scale, tardive dyskinesia, 56:53
 age, magnetic resonance imaging, 60:117
 age of onset, anticipation, 59:25
 age of onset, genetics, 59:25
 age, white matter hyperintensity, 60:117
 Allen Cognitive Levels, cross-cultural, African-American, Mexican-American, 56:101
 ambidexterity, laterality, 59:119
 anhedonia, laterality, 56:163
 anhedonia, skin conductance, 56:163
 anticipation, age of onset, 59:25
 anticipation, genetics, 59:25
 arachidonic acid, phospholipids, 60:11
 attention, backward masking, 60:49
 attention, Continuous Performance Test, 57:131, 60:49, 60:155
 attention, disorganized symptoms, 57:241
 attention, evoked potentials, P300 component, 58:69
 attention, eye movements, 59:221
 attention, heart rate, 57:241
 attention, negative symptoms, 57:241
 attention, neuroleptic effects, 57:131
 attention, Pigache Attention Task, 60:155
 attention, positive symptoms, 57:241
 attention, reaction time, 58:69
 attention, sex differences, 59:213
 attention, skin conductance, 57:241

attention, social cue perception, 56:111

attention, social skill, 59:213
 attention, tardive dyskinesia, 59:221
 attention, tone discrimination, 57:75
 backward masking, attention, cognition, 60:49
 blood pressure, body temperature, 57:21
 blood pressure, circadian rhythm, 57:21
 blood pressure, heart rate, 57:21
 blood pressure, norepinephrine, 57:21
 body temperature, circadian rhythm, 57:21
 Borna Disease virus, magnetic resonance imaging, 56:33
 Brown-Peterson paradigm, frontal lobe, 56:155
 calbindin, frontal lobe, local circuit neurons, 59:81
 calbindin, γ -aminobutyric acid, 59:81
 calretinin, frontal lobe, local circuit neurons, 59:81
 calretinin, γ -aminobutyric acid, 59:81
 Cambridge Neurological Inventory, extrapyramidal signs, motor coordination, soft signs, 56:183
 catatonic subtype, genetics, pseudoautosomal inheritance, 59:17
 catatonic subtype, sex concordance, 59:17
 caudate nucleus, positron emission tomography, 58:53
 circadian rhythm, blood pressure, 57:21
 circadian rhythm, body temperature, 57:21
 circadian rhythm, cortisol, 57:21
 circadian rhythm, heart rate, 57:21
 circadian rhythm, norepinephrine, 57:21
 circadian rhythm, thyroid hormones, 57:21
 circadian rhythm, Abnormal Involuntary Movements Scale, 56:53
 circadian rhythm, photoperiod, 60:199
 circadian rhythm, tardive dyskinesia, 56:53
 circadian rhythm, violence, 60:199
 circannual rhythm, photoperiod, 60:199
 circannual rhythm, violence, 60:199
 cognition, Allen Cognitive Levels, 56:101
 cognition, attention, 59:213
 cognition, attention, 60:49
 cognition, attention, 60:147
 cognition, backward masking, 60:49
 cognition, Brown-Peterson paradigm, 56:155
 cognition, cross-cultural, 56:101
 cognition, frontal lobe, 56:155
 cognition, memory, 56:155, 57:141
 cognition, Selective Attention Test, 60:147
 cognition, social skill, 57:141, 59:213
 cognition, Wisconsin Card Sorting Test, 56:45
 cognition, work performance, 56:45
 communication deviance, expressed emotion, 56:121
 communication deviance, family interactions, 56:121
 communication deviance, prognosis, 56:121
 communication deviance, schizoaffective disorder, 56:121
 communication deviance, social skills, 56:121
 computed tomography, schizotypal personality disorder, 57:109
 computed tomography, ventricle-brain ratio, 57:109, 60:147
 content analysis, expressed emotion, 57:155
 content analysis, family environment, 57:155

content analysis, speech, 57:155

Continuous Performance Test, attention, 57:131, 60:49, 60:155

Continuous Performance Test, backward masking, 60:49

Continuous Performance Test, distractibility, 57:131

Continuous Performance Test, neuroleptic effects, 57:131

Continuous Performance Test vs. Pigache Attention Task, 60:155

cortisol, circadian rhythm, 57:21

cross-cultural, Allen Cognitive Levels, African-American, Mexican-American, 56:101

deficit syndrome, monoamine oxidase, 56:25

disorganization symptoms, neuropsychology, 58:227

disorganized symptoms, attention, 57:241

disorganized symptoms, heart rate, 57:241

disorganized symptoms, skin conductance, 57:241

dopamine transporter gene, French population, 59:1

dopamine transporter gene, linkage analysis, 59:1

elderly patients, magnetic resonance imaging, 60:117

elderly patients, white matter hyperintensity, 60:117

electroencephalography, evoked potentials, 56:229, 56:237, 56:271

electroencephalography, Lyapunov exponent, nonlinear analysis, 56:257

electroencephalography, P50 evoked potential component, 56:271

electrooculography, frontal eye fields, positron emission tomography, 58:53

epidemiology, season of birth, 60:205

epidemiology, Southern Hemisphere, 60:205

evoked potentials, attention, 58:69

evoked potentials, gating, 56:271

evoked potentials, late component, 56:229

evoked potentials, oddball paradigm, 56:237

evoked potentials, P300 component, 58:69

evoked potentials, P50 component, 56:271

evoked potentials, reaction time, 58:69

evoked potentials, variance, medication effects, 56:229, 56:237

expressed emotion, communication deviance, 56:121

expressed emotion, content analysis, 57:155

expressed emotion, family environment, 57:155

expressed emotion, family interactions, 56:121

expressed emotion, prognosis, 56:121

expressed emotion, social skills, 56:121

expressed emotion, speech analysis, 57:155

extrapyramidal signs, Cambridge Neurological Inventory, 56:183

extrapyramidal signs, motor coordination, 56:183

extrapyramidal signs, neurological soft signs, 56:183

eye movements, attention, 59:221

eye movements, caudate nucleus, positron emission tomography, 58:53

eye movements, smooth pursuit, 58:53, 59:221

eye movements, tardive dyskinesia, 59:221

family environment, expressed emotion, 57:155

family interactions, communication deviance, 56:121

family interactions, expressed emotion, 56:121

family interactions, prognosis, 56:121

family interactions, social skills, 56:121

French population, dopamine transporter gene, 59:1

French population, linkage analysis, 59:1

frontal cortex, magnetic resonance spectroscopy, 57:91

frontal cortex, phosphomonoesters, 57:91

frontal eye fields, caudate nucleus, 58:53

frontal eye fields, positron emission tomography, 58:53

frontal lobe, Brown-Peterson paradigm, 56:155

frontal lobe, calbindin, calretinin, 59:81

frontal lobe, cognition, 56:155

frontal lobe, γ -aminobutyric acid, 59:81

frontal lobe, local circuit neurons, 59:81

frontal lobe, memory, 56:155

frontal lobe, neuropsychology, 56:155

frontal lobe, post-mortem study, 59:81

γ -aminobutyric acid, calbindin, calretinin, 59:81

γ -aminobutyric acid, frontal lobe, 59:81

γ -aminobutyric acid, local circuit neurons, 59:81

γ -aminobutyric acid, post-mortem study, 59:81

gating, evoked potentials, P50 component, 56:271

genetics, age of onset, 59:25

genetics, anticipation, 59:25

genetics, catatonic subtype, 59:17

genetics, dopamine transporter gene, French population, 59:1

genetics, IQ, 56:135

genetics, linkage analysis, 59:1

genetics, pseudoautosomal inheritance, 59:17

genetics, sex concordance, 59:17

gonadotropin, gonadotropin-releasing hormone, luteinizing hormone, testosterone, 57:231

gonadotropin-releasing hormone, gonadotropin, luteinizing hormone, testosterone, 57:231

haloperidol, Abnormal Involuntary Movements Scale, 56:53

haloperidol, circadian rhythm, 56:53

haloperidol, positive and negative symptoms, 57:49

haloperidol, skin conductance, 57:49

haloperidol, tardive dyskinesia, 56:53

haloperidol, ketone reductase, 57:101

haloperidol, reduced haloperidol, 57:101

heart rate, attention, 57:241

heart rate, blood pressure, body temperature, 57:21

heart rate, circadian rhythm, 57:21

5-hydroxyindoleacetic acid, meta-analysis, 59:239

5-hydroxyindoleacetic acid, serotonin, 59:161, 59:239

5-hydroxyindoleacetic acid, violence, 59:161

immunology, Borna Disease virus, 56:33

immunology, magnetic resonance imaging, 56:33

IQ, genetics, matching fallacy, neuropsychology, 56:135

ketone reductase, haloperidol, 57:101

ketone reductase, reduced haloperidol, 57:101

laterality, ambidexterity, 59:119

laterality, anhedonia, 56:163

laterality, motor activity, 57:279

laterality, skin conductance, 56:163

linkage analysis, dopamine transporter gene, French population, 59:1

luteinizing hormone, gonadotropin-releasing hormone, 57:231

luteinizing hormone, testosterone, 57:231

Lyapunov exponent, electroencephalography, nonlinear analysis, 56:257

Lyapunov exponent, polysomnography, rapid eye movement sleep stage, 56:257

magnetic resonance imaging, age, 60:117

magnetic resonance imaging, Borna disease virus, 56:33

magnetic resonance imaging, elderly patients, 60:117

magnetic resonance imaging, putamen, 56:33

magnetic resonance imaging, white matter hyperintensity, 60:117

magnetic resonance spectroscopy, frontal cortex, phosphomonoesters, 57:91

memory, 56:155, 57:141, 60:135

meta-analysis, hydroxyindoleacetic acid, 59:239

milieu therapy, neuroleptic treatment, outcome prediction, 58:77

milieu therapy, paranoid subtype, 58:77

milieu therapy, patients' global assessments, 58:77

monoamine oxidase, deficit syndrome, negative symptoms, 56:25

motor activity, laterality, 57:279

motor coordination, Cambridge Neurological Inventory, 56:183

negative symptoms, attention, 57:241

negative symptoms, deficit syndrome, 56:25

negative symptoms, diagnosis, 56:25

negative symptoms, haloperidol, 57:49

negative symptoms, heart rate, 57:241

negative symptoms, monoamine oxidase, 56:25

negative symptoms, neuropsychology, 58:45, 58:227

negative symptoms, skin conductance, 57:49, 57:241

negative symptoms, Wisconsin Card Sorting Test, 58:45

neuroleptic effects, attention, 57:131

neuroleptic effects, Continuous Performance Test, 57:131

neuroleptic effects, distractibility, 57:131

neuroleptic effects, evoked potentials, 56:229

neuroleptic treatment, milieu therapy, 58:77

neuroleptic treatment, outcome prediction, 58:77

neuroleptic treatment, paranoid subtype, 58:77

neuroleptic treatment, patients' global assessments, 58:77

neuroleptic treatment, peptides, 58:171

neurological soft signs, Cambridge Neurological Inventory, 56:183

neuropsychology, attention, 56:111, 59:213

neuropsychology, Brown-Peterson paradigm, 56:155

neuropsychology, cognition, 56:45, 56:155, 59:213

neuropsychology, disorganization symptoms, 58:227

neuropsychology, frontal lobe, 56:155

neuropsychology, genetics, IQ, matching fallacy, 56:135

neuropsychology, memory, 56:155, 60:135

neuropsychology, negative symptoms, 58:45, 58:227

neuropsychology, paired associate recognition, 60:135

neuropsychology, positive symptoms, 58:45, 58:227

neuropsychology, social cue perception, 56:111

neuropsychology, social skill, 59:213

neuropsychology, Wisconsin Card Sorting Test, 56:45, 58:45, 60:135

neuropsychology, work performance, 56:45

nonlinear analysis, electroencephalography, Lyapunov exponent, 56:257

nonlinear analysis, polysomnography, rapid eye movement sleep stage, 56:257

norepinephrine, blood pressure, circadian rhythm, 57:21

olfactory projections, orbitofrontal cortex, positron emission tomography, 60:113

orbitofrontal cortex, olfactory projections, positron emission tomography, 60:113

outcome prediction, milieu therapy, neuroleptic treatment, 58:77

outcome prediction, paranoid subtype, 58:77

outcome prediction, patients' global assessments, 58:77

outcome, role in diagnosis, 59:109

outcome, schizophreniform disorder, 59:109

paired associate recognition, neuropsychology, 60:135

paranoid subtype, milieu therapy, neuroleptic treatment, 58:77

paranoid subtype, outcome prediction, 58:77

paranoid subtype, patients' global assessments, 58:77

phospholipids, arachidonic acid, 60:11

phosphomonoesters, frontal cortex, magnetic resonance spectroscopy, 57:91

photoperiod, circadian and circannual rhythm, 60:199

photoperiod, violence, 60:199

Pigache Attention Task vs. Continuous Performance Test, 60:155

polysomnography, computed tomography, 60:125

polysomnography, Lyapunov exponent, 56:257

polysomnography, magnetic resonance spectroscopy, 57:91

polysomnography, nonlinear analysis, 56:257

polysomnography, rapid eye movement sleep stage, 56:257, 59:203

polysomnography, slow wave sleep, 57:91, 59:203, 60:125

positive symptoms, attention, 57:241

positive symptoms, haloperidol, 57:49

positive symptoms, heart rate, 57:241

positive symptoms, neuropsychology, 58:45, 58:227

positive symptoms, skin conductance, 57:49, 57:241

positive symptoms, Wisconsin Card Sorting Test, 58:45

positron emission tomography, caudate nucleus, frontal eye fields, 58:53

positron emission tomography, olfaction, orbitofrontal cortex, 60:113

prognosis, communication deviance, expressed emotion, family interactions, 56:121

prognosis, social skills, 56:121

prolyl endopeptidase, 58:217

pseudoautosomal inheritance, catatonic subtype, sex concordance, 59:17

putamen, Borna Disease virus, magnetic resonance imaging, 56:33

rapid eye movement sleep, 56:257, 56:271, 59:203

reaction time, attention, evoked potential P300 component, 58:69

reduced haloperidol, ketone reductase, 57:101

schizoaffective disorder, Allen Cognitive Levels, 56:101

schizoaffective disorder, anhedonia, 56:163

schizoaffective disorder, attention, 57:241

schizoaffective disorder, cognition, 56:45, 56:101, 57:141
 schizoaffective disorder, communication deviance, 56:121
 schizoaffective disorder, cross-cultural comparison, African-American, Mexican-American, 56:101
 schizoaffective disorder, disorganized symptoms, 57:241
 schizoaffective disorder, expressed emotion, family interactions, 56:121
 schizoaffective disorder, heart rate, 57:241
 schizoaffective disorder, laterality, 56:163
 schizoaffective disorder, memory, 57:141
 schizoaffective disorder, negative symptoms, 57:241, 58:45
 schizoaffective disorder, neuropsychology, 56:45
 schizoaffective disorder, neuropsychology, 58:45
 schizoaffective disorder, positive symptoms, 57:241, 58:45
 schizoaffective disorder, prognosis, 56:121
 schizoaffective disorder, sex, 57:141
 schizoaffective disorder, skin conductance, 56:163, 57:241
 schizoaffective disorder, social skill, 56:121, 57:141
 schizoaffective disorder, Wisconsin Card Sorting Test, 56:45
 schizoaffective disorder, work performance, 56:45
 schizophreniform disorder, diagnosis, outcome, 59:109
 season of birth, epidemiology, Southern Hemisphere, 60:205
 Selective Attention Test, 60:147
 serotonin, 5-hydroxyindoleacetic acid, 59:161, 59:239
 serotonin, meta-analysis, statistics, 59:239
 serotonin, violence, 59:161
 sex concordance, catatonic subtype, 59:17
 skin conductance, anhedonia, 56:163
 skin conductance, attention, 57:241
 skin conductance, disorganized symptoms, 57:241
 skin conductance, haloperidol, 57:49
 skin conductance, laterality, 56:163
 skin conductance, negative symptoms, 57:49, 57:241
 skin conductance, positive symptoms, 57:49, 57:241
 skin conductance, schizoaffective disorder, 56:163, 57:241
 sleep, computed tomography, 60:125
 sleep, evoked potentials, P50 component, 56:271
 sleep, frontal cortex, 57:91
 sleep, gating, 56:271
 sleep, Lyapunov exponent, nonlinear analysis, 56:257
 sleep, magnetic resonance spectroscopy, phosphomonoesters, 57:91
 sleep, rapid eye movement, 56:257, 56:271, 59:203
 sleep, slow wave sleep, 56:271, 57:91, 59:203, 60:125
 sleep, ventricle-brain ratio, 60:125
 slow wave sleep, computed tomography, ventricle-brain ratio, 60:125
 slow wave sleep, evoked potentials, 56:271
 slow wave sleep, frontal cortex, 57:91
 slow wave sleep, gating, 56:271
 slow wave sleep, magnetic resonance spectroscopy, phosphomonoesters, 57:91
 social cue perception, neuropsychology, 56:111
 social skill, attention, 59:213
 social skill, cognition, 57:141, 59:213
 social skill, communication deviance, 56:121
 social skill, expressed emotion, 56:121
 social skill, family interactions, 56:121
 social skill, memory, 57:141
 social skill, neuropsychology, 59:213
 social skills, prognosis, 56:121
 speech, content analysis, expressed emotion, family environment, 57:155
 statistics, meta-analysis, 5-hydroxyindoleacetic acid, serotonin, 59:239
 tardive dyskinesia, Abnormal Involuntary Movements Scale, 56:53
 tardive dyskinesia, attention, 59:221
 tardive dyskinesia, circadian rhythm, 56:53
 tardive dyskinesia, eye movements, smooth pursuit tracking, 59:221
 testosterone, gonadotropin, gonadotropin releasing hormone, luteinizing hormone, 57:231
 thyroid hormones, circadian rhythm, 57:21
 tone discrimination, attention, 57:75
 valproate, prolyl endopeptidase, 58:217
 ventricle-brain ratio, computed tomography, 57:109, 60:125
 violence, circadian and circannual rhythm, 60:199
 violence, 5-hydroxyindoleacetic acid, 59:161
 violence, photoperiod, 60:199
 violence, serotonin, 59:161
 white matter hyperintensity, age, 60:117
 white matter hyperintensity, elderly patients, 60:117
 white matter hyperintensity, magnetic resonance imaging, 60:117
 Wisconsin Card Sorting Test, positive and negative symptoms, 58:45
 Wisconsin Card Sorting Test, schizoaffective disorder, 56:45, 58:45
 Wisconsin Card Sorting Test, work performance, 56:45
 work performance, neuropsychology, 56:45
 work performance, schizoaffective disorder, 56:45
 work performance, Wisconsin Card Sorting Test, 56:45

Schizophreniform disorder. See Schizophrenia

Schizotypal personality

attention, backward masking, Continuous Performance Test, 60:49
 backward masking, attention, 60:49
 cognition, neuropsychology, 59:127
 computed tomography, ventricle-brain ratio, 57:109
 Continuous Performance Test, attention, 60:49
 laterality, memory, 56:71
 laterality, neuropsychology, 56:71
 memory, laterality, 56:71
 memory, neuropsychology, 56:71
 neuropsychology, cognition, 59:127
 neuropsychology, laterality, 56:71
 neuropsychology, memory, 56:71
 ventricle-brain ratio, computed tomography, 57:109

Serotonin

affective disorder, computed tomography, 60:33
 affective disorder, paroxetine, 58:117, 59:189
 alcohol dependence, intracellular calcium, 57:275
 Alzheimer's Disease, pharmacokinetics, platelets, 59:145

anxiety disorder, 5-hydroxyindoleacetic acid, 57:1
 attention deficit hyperactivity disorder, oppositional-defiant disorder, 57:13
 autism, β -endorphin, naltrexone, 58:191
 β -endorphin, autism, 58:191
 borderline personality, meta-chlorophenylpiperazine, 58:161
 bufotenin, personality, violence, 58:145
 computed tomography, affective disorder, 60:33
 conduct disorder, oppositional-defiant disorder, 57:13
 dementia, pharmacokinetics, platelets, 59:145
 genetics, attention deficit hyperactivity disorder, conduct disorder, oppositional-defiant disorder, 57:13
 5-hydroxyindoleacetic acid, anxiety disorder, 57:1
 5-hydroxyindoleacetic acid, meta-analysis, 59:239
 5-hydroxyindoleacetic acid, schizophrenia, 59:161, 59:239
 5-hydroxyindoleacetic acid, statistics, 59:239
 5-hydroxyindoleacetic acid, violence, 59:161
 imipramine, pharmacokinetics, 59:189
 impulsivity, paroxetine, 60:177
 meta-analysis, 5-hydroxyindoleacetic acid, serotonin, schizophrenia, 59:239
 meta-chlorophenylpiperazine, borderline personality, 58:161
 meta-chlorophenylpiperazine, obsessive-compulsive disorder, 58:161
 meta-chlorophenylpiperazine, panic disorder, 58:161
 meta-chlorophenylpiperazine, personality disorder, 58:161
 meta-chlorophenylpiperazine, pindolol, 58:89
 meta-chlorophenylpiperazine, social phobia, 58:161
 naltrexone, autism, 58:191
 obsessive-compulsive disorder, meta-chlorophenylpiperazine, 58:161
 obsessive-compulsive disorder, paroxetine binding, 58:117
 ondansetron, affective disorder, computed tomography, 60:33
 oppositional-defiant disorder, genetics, 57:13
 panic disorder, meta-chlorophenylpiperazine, 58:161
 panic disorder, personality disorder, 58:161
 paroxetine, affective disorder, 58:117, 59:189
 paroxetine binding, obsessive-compulsive disorder, 58:117
 paroxetine binding, platelet, 58:117
 paroxetine, impulsivity, 60:177
 paroxetine, pharmacokinetics, 59:189
 personality, bufotenin, 58:145
 personality disorder, meta-chlorophenylpiperazine, 58:161
 personality, impulsivity, paroxetine, 60:177
 personality, violence, 58:145
 pindolol, meta-chlorophenylpiperazine, 58:89
 schizophrenia, 5-hydroxyindoleacetic acid, serotonin, meta-analysis, 59:161, 59:239
 schizophrenia, statistics, 59:239
 schizophrenia, violence, 59:161
 social phobia, meta-chlorophenylpiperazine, 58:161
 statistics, meta-analysis, 5-hydroxyindoleacetic acid, serotonin, schizophrenia, 59:239
 violence, bufotenin, 58:145
 violence, 5-hydroxyindoleacetic acid, 59:161
 violence, personality, 58:145
 violence, schizophrenia, 59:161

Sex

affective disorder, epidemiology, 58:1
 anxiety disorder, epidemiology, 58:1
 cognition, memory, schizoaffective disorder, schizophrenia, social skill, 57:141
 epidemiology, affective disorder, anxiety disorder, 58:1
 memory, schizoaffective disorder, schizophrenia, social skill, 57:141
 schizoaffective disorder, cognition, memory, social skill, 57:141
 schizophrenia, cognition, memory, social skill, 57:141
 social skill, cognition, memory, schizoaffective disorder, schizophrenia, 57:141

Skin conductance

affective disorder, anhedonia, 56:163
 affective disorder, bipolar subtype, 56:163
 affective disorder, laterality, 56:163
 anhedonia, bipolar affective disorder, laterality, 56:163
 anhedonia, schizoaffective disorder, schizophrenia, 56:163
 bipolar affective disorder, anhedonia, laterality, 56:163
 disorganized symptoms, schizoaffective disorder, schizophrenia, 57:241
 haloperidol, positive and negative symptoms, schizophrenia, 57:49
 laterality, bipolar affective disorder, anhedonia, 56:163
 laterality, schizoaffective disorder, schizophrenia, 56:163
 negative symptoms, schizoaffective disorder, 57:241
 negative symptoms, schizophrenia, 57:49, 57:241
 positive symptoms, haloperidol, 57:49
 positive symptoms, schizoaffective disorder, 57:241
 positive symptoms, schizophrenia, 57:49, 57:241
 schizoaffective disorder, anhedonia, 56:163
 schizoaffective disorder, disorganized symptoms, 57:241
 schizoaffective disorder, laterality, 56:163
 schizoaffective disorder, positive and negative symptoms, 57:241
 schizophrenia, anhedonia, 56:163
 schizophrenia, disorganized symptoms, 57:241
 schizophrenia, haloperidol, 57:49
 schizophrenia, laterality, 56:163
 schizophrenia, positive and negative symptoms, 57:49, 57:241

Sleep. *See Polysomnography; Sleep deprivation*

Sleep deprivation

affective disorder, Arden ratio, electrooculography, 57:197
 circadian rhythm, visual adaptation, 57:197
 electrooculography, circadian rhythm, visual adaptation, 57:197

Social phobia

neuropeptide Y, stress, 59:183
 norepinephrine, stress, 59:183
 peptides, stress, 59:183
 stress, neuropeptide Y, 59:183
 stress, norepinephrine, 59:183
 stress, peptides, 59:183

Social skill

attention, cognition, neuropsychology, schizophrenia, sex effects, 59:213

Statistics

meta-analysis, 5-hydroxyindoleacetic acid, serotonin, schizophrenia, 59:239

Stress. *See Child abuse; Peptides; Posttraumatic stress disorder*

Structured Clinical Interview for BICDSM-III-RBIC

anxiety, human immunodeficiency virus, intake interview, 59:245

depression, human immunodeficiency virus, intake interview, 59:245

human immunodeficiency virus, anxiety, depression, intake interview, 59:245

Substance dependence

age, genetics, race, sex, 56:213

alcohol, cocaine, marijuana, electroencephalography, 58:247

cocaine, alcohol, 58:247

cocaine, crack, cognition, 60:167

cocaine, marijuana, electroencephalography, 58:247

cocaine, crack, neuropsychology, 60:167

cognition, cocaine, crack, 60:167

comorbid depression, heroin, 58:153

electroencephalography, alcohol, cocaine, marijuana, 58:247

epidemiology, genetics, 57:169

Family History Screen for Epidemiologic Studies, genetics, 57:169

fenfluramine, heroin, 58:153

genetics, **Family History Screen for Epidemiologic Studies**, 57:169

genetics, race, sex, 56:213

genetics, twin study, 56:213

heroin abuse, comorbid depression, 58:153

marijuana, alcohol, cocaine, electroencephalography, 58:247

neuropsychology, cocaine, crack, 60:167

prolactin, heroin abuse, 58:153

race, age, sex, genetics, 56:213

sex, age, race, genetics, 56:213

twin study, age, sex, race, 56:213

Tardive dyskinesia

Abnormal Involuntary Movements Scale, circadian rhythm, 56:53

Abnormal Involuntary Movements Scale, haloperidol, 56:53

Abnormal Involuntary Movements Scale, schizophrenia, 56:53

circadian rhythm, Abnormal Involuntary Movements Scale, 56:53

haloperidol, Abnormal Involuntary Movements Scale, schizophrenia, 56:53

schizophrenia, circadian rhythm, 56:53

Thyroid hormones

affective disorder, thyroid-stimulating hormone, 57:41

affective disorder, thyrotropin-releasing hormone, 57:41

circadian rhythm, schizophrenia, 57:21

schizophrenia, circadian rhythm, 57:21

thyroid-stimulating hormone, affective disorder, 57:41

thyrotropin-releasing hormone, affective disorder, 57:41

Tridimensional Personality Questionnaire

affective disorder, bipolar subtype, 57:209, 58:139

affective disorder, harm avoidance, 57:209, 58:139

affective disorder, novelty seeking, 58:139

affective disorder, unipolar subtype, 58:139

bipolar affective disorder, harm avoidance, 57:209, 58:139

bipolar affective disorder, novelty seeking, 58:139

harm avoidance, affective disorder, bipolar subtype, 57:209, 58:139

harm avoidance, unipolar subtype, 58:139

novelty seeking, affective disorder, bipolar subtype, 58:139

novelty seeking, unipolar subtype, 58:139

Vanillylmandelic acid

anxiety disorder, norepinephrine, 57:1

norepinephrine, anxiety disorder, 57:1

Ventricle-brain ratio. *See Computed tomography***Violence**

affective disorder, circadian and circannual rhythm, photoperiod, 60:199

bufotenin, personality type, serotonin, 58:145

circadian rhythm, affective disorder, schizophrenia, 60:199

circannual rhythm, affective disorder, schizophrenia, 60:199

5-hydroxyindoleacetic acid, schizophrenia, 59:161

schizophrenia, circadian and circannual rhythm, 60:199

schizophrenia, 5-hydroxyindoleacetic acid, serotonin, 59:161

serotonin, bufotenin, 58:145

serotonin, schizophrenia, 59:161